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Abstract of the Dissertation 
Viral MHC Class I Evasion Affects Anti-viral T Cell Development and Responses  
Elvin J. Lauron 
Doctor of Philosophy in Biology and Biomedical Sciences 
Molecular Microbiology and Microbial Pathogenesis 
Washington University in St. Louis, 2018 
Professor Wayne M. Yokoyama, Chair 
 
Cytotoxic CD8+ T cells (CTLs) play a critical role in protective immunity against viruses, 
which is underscored by the evolution of viral CTL evasion mechanisms. For instance, many 
viruses commonly target the major histocompatibility complex class I (MHCI) antigen 
presentation pathway to prevent CTLs from recognizing infected cells. A striking example of this 
is cowpox virus (CPXV), which interferes with MHCI antigen presentation through two distinct 
mechanisms. One mechanism of CPXV-mediated MHCI inhibition is to retain MHCI molecules 
in the endoplasmic reticulum (ER). The second mechanism is to prevent antigen peptide loading 
onto MHCI molecules. These mechanisms when combined result in potent inhibition of MHCI 
antigen presentation and effective evasion of CPXV-specific CTL responses in vivo. However, it 
is unclear how viral MHCI inhibition affects the CTL repertoire and the subsequent development 
of memory CD8+ T cells. Furthermore, the effects of viral MHCI inhibition on local memory 
CD8+ T cell responses during peripheral CPXV infection has not been examined.  
To explore these issues, I used the CPXV murine infection model to compare CD8+ T 
cell responses against CPXV and a recombinant CPXV mutant that is incapable of inhibiting 
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MHCI antigen presentation. Here, I demonstrate that viral MHCI inhibition affects the local CTL 
and memory CD8+ T cell repertoire in specific niches. Primary anti-CPXV responses and 
memory responses were shaped by antigen abundance and CD8+ T cell cross-competition for 
viral peptide-MHCI complexes on the cell surface of antigen presenting cells (APCs), 
respectively. Additionally, I show that the overall quality and quantity of CTL and memory 
CD8+ T cells is unaffected by viral MHCI inhibition following CPXV infection. Finally, I 
determined that viral MHCI inhibition contributes to evasion of local memory CD8+ T cell 
responses. Collectively, the results of these studies provide insight on determinants that influence 
the anti-viral CD8+ T cell repertoire, local memory formation, and local memory responses. 
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Chapter 1: 
Introduction 
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Introduction to orthopoxviruses 
Orthopoxviruses are large DNA viruses capable of causing devastating disease in humans 
and a wide range of animal hosts. This broad host range is a feature of zoonotic orthopoxviruses, 
such as cowpox virus (CPXV) and monkeypox virus (MPXV). Moreover, human MPXV 
incidence has increased over 20-fold since cessation of vaccinia virus (VACV) smallpox 
vaccination1, which previously provided cross-protection against MPXV, CPXV, and related 
orthopoxviruses. The capacity of orthopoxviruses to infect a wide range of hosts is attributed to 
their large genomes that encode a plethora of immunomodulatory proteins. Accordingly, some of 
these immunoevasin proteins exhibit broad host-specificity. Here I highlight the interplay 
between orthopoxvirus immunoevasins and the host immune response and discuss open 
questions in regards to the effects of viral immune evasion. 
Innate immunity against orthopoxvirus infection 
The innate immune response can be triggered when conserved structures on pathogens, 
known as pathogen associated molecular patterns (PAMPs), are detected. PAMPs are detected by 
pattern recognition receptors (PRRs), which can induce signaling cascades that ultimately 
converge to activate the interferon regulatory factor 3 (IRF3) and nuclear factor kappa-light-
chain enhancer of activated B cells (Nf-κB)2. These transcription factors promote the expression 
of proinflammatory cytokines and type I interferons (IFNs), resulting in a potent antiviral state. 
This antiviral state can be initiated at several early points during orthopoxvirus infection. At the 
earliest stage of infection, orthopoxviruses can be sensed when extracellular virions come in 
contact with cells via toll-like receptor (TLR) 4, a cell surface PRR. TLR4 signaling restricts 
viral replication and protects mice against VACV infection, as mice that are TLR4-deficient are 
more susceptible to infection with VACV3.  
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VACV is also recognized at the stage of viral entry by several endosomal PRRs that 
recognize pathogen-derived nucleic acids, including TLR3, 7, 8, and 94–7. Mice that are deficient 
in TLR9 are also highly susceptible to orthopoxvirus infection7, while mice infected with lethal 
orthopoxvirus survive when TLR9 is activated. Conversely, TLR3 signaling plays a negative role 
during orthopoxvirus infection, as mice lacking TLR3 are less susceptible to VACV infection, 
presumably due to excessive inflammation caused by TLR3 signaling. VACV DNA can also 
activate TLR75, yet VACV infected cells do not produce IFN-α or the proinflammatory cytokine 
tumor necrosis factor (TNF) through TLR7 signaling. The antiviral defense mechanisms remain 
unclear for TLR7 signaling, whereas TLR4, 8, and 9-mediated innate immunity is known to 
activate Nf-κB and IRF3 to induce proinflammatory cytokine and type I IFN production. 
However, the production of IFN and proinflamatory cytokines is not completely dependent on 
TLRs during orthopoxvirus infection3,7,8.  
Orthopoxviruses can induce expression of antiviral cytokines through retinoic acid-
inducible gene 1 (RIG-I)-like receptors (RLRs) and cytosolic double- stranded DNA (dsDNA) 
sensors (CDSs), which are cytosolic PRRs of RNA and DNA respectively. More recently, the 
cytosolic sensors activating cyclic guanosine monophosphate-adenosine monophosphate 
synthase (cGAS) was identified as a cytosolic DNA sensor with strong antiviral effects against 
orthopoxviruses9,10. The importance of cGAS in antiviral innate immunity against 
orthopoxviruses was similarly demonstrated with infections in mice that lack cGAS10. The 
protective effects of cGAS are likewise mediated by Nf-κB, IRF3, and type I IFN. These 
important factors are linked to RLR-mediated innate immunity against orthopoxviruses as well. 
Important RLRs involved in controlling orthopoxvirus infections include RIG-I, melanoma 
differentiation-associated protein 5 (MDA5), and laboratory of genetics and physiology 2 
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(LGp2)11–13. Protein kinase RNA-activated (PKR), although not an RLR, also plays an important 
role in inducing type I IFN production upon sensing orthopoxvirus-derived RNA. PKR is 
particularly important since activated PKR can elicit additional antiviral defense mechanisms, 
such as apoptosis12.  
Nonetheless, orthopoxviruses have evolved mechanisms to efficiently target the signaling 
pathways of these PRRs and the activation of Nf-κB and IRF3, highlighting the importance of 
these factors in the orthopoxvirus-induced innate immune response. 
Orthopoxvirus evasion of innate immune responses 
 The central role for IRF3 and Nf-κB in innate immunity applies strong evolutionary 
pressure for orthopoxviruses to evolve mechanisms of IRF3 and Nf-κB antagonism. Indeed, 
orthopoxvirus immunoevasins can target the activation of IRF3 and Nf-κB directly or target 
activating signaling pathways proximally. For example, the VACV proteins A46 and A52 can 
disrupt TLR-mediated activation of Nf-κB by inhibiting the proximal signal transducers TNF 
receptor-associated factor 6 (TRAF6) and Myd88 adapter-like (Mal) respectively. The receptor-
proximal adaptor proteins MyD88 and Mal initiate signal cascades when TLRs are stimulated.  
MyD88 and Mal activate the IL-1 receptor-associated kinase (IRAK) or IRAK2, which in turn 
recruits TRAF614. TRAF6 is essential to activate TGF-β-activated kinase 1 (TAK1) and TAK1 
binding protein 1 (TAB1) dependent phosphorylation of IκB kinase (IKK)15, which is normally 
in complex with Nf-κB. Phosphorylated IKK results in activated Nf-κB. The VACV protein N1 
inhibits Nf-κB from being activated by associating with IKK16. The VACV protein B14 and C4 
also inhibits activated IKK16,17. Importantly, C4, B14, A46, and A52 are virulence factors as 
VACV mutants that lack these factors are attenuated in vivo17–20. The VACV mutant VV811 
lacks 55 open reading frames (ORFs) and is missing all the known Nf-κB inhibitors. 
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Intriguingly, VV811 can still inhibit Nf-κB21, suggesting that other Nf-κB inhibitors likely 
remain to be identified.  
 Additional poxvirus-encoded inhibitors include secreted soluble proteins that bind to 
cytokines capable of inducing Nf-κB activity, thereby blocking cytokine-receptor interactions 
and Nf-κB signaling. One commonly targeted cytokine is TNF, which can be intercepted by the 
T2 protein from shope fibroma virus (SFV) and myxoma virus (MYXV) 22,23. T2 plays a critical 
role in MYXV pathogenesis since the absence of T2 attenuates MYXV in vivo23. Similarly, TNF 
binding proteins encoded by CPXV, known as cytokine response modifier (Crm) B, C, D and E, 
have been shown to neutralize TNF23–25 and contribute to CPXV pathogenesis27. Crm B 
orthologues are present in the genomes of multiple orthopoxviruses, including MPXV, 
ectromelia virus (ECTV), and VARV28; as emphasized by the conservation of these 
orthopoxvirus TNF inhibitors, orthopoxvirus fitness largely impinges on inhibiting the function 
of TNF. TNF can also synergistically induce Nf-κB activity in combination with other cytokines 
such as IFN-γ29. CONCLUSION? 
 IFN-γ is a proinflammatory cytokine that is critical in mediating anti-orthopoxvirus 
immunity30–32 and is also a target of orthopoxvirus-encoded cytokine inhibitors. The secreted 
IFN-γ binding protein B8 can neutralize rat, rabbit, bovine, human, equine and mouse IFN-γ and 
is conserved among orthopoxviruses33,34. Deletion of B8R from the genome of ECTV 
significantly attenuates ECTV pathogenesis in an IFN-γ dependent manner35. In contrast, 
deletion of B8R does not have any effects on VACV and CPXV pathogenesis in mice33,36. This 
may be explained by the fact that B8 from VACV and CPXV does not bind to mouse IFN-γ, yet 
it is possible that VACV/CPXV B8 has alternative cytokine targets or redundant 
immunomodulatory functions in mice. Interestingly, B8 also contains a conserved epitope that 
 
 
6 
elicits a strong immunodominant CD8+ T cell response in orthopoxvirus-infected mice bearing 
the major histocompatibility complex class I (MHCI) haplotype H2b31,35–37. ßMAYBE BETTER 
TO BRING UP  LATER? 
CONCLUSION? 
OVERALL CONCLUSION FOR SECTION? 
Adaptive immunity against orthopoxvirus infection 
 CD8+ T cells are an important arm of the adaptive immune response and play a critical 
role in controlling orthopoxvirus infections. Before gaining anti-viral effector functions, CD8+ T 
cells must be primed by antigen presenting cells (APCs) that present endogenous pathogen-
derived epitopes via MHCI molecules, a process known as direct presentation. Exogenous 
antigens can also be processed through the MHCI antigen presentation pathway and presented by 
APCs through a process known as cross-presentation. Upon encountering cognate antigen 
epitopes presented by APCs, CD8+ T cells differentiate into cytotoxic CD8+ T cells (CTLs) and 
mediate viral resistance directly by killing infected cells through secretion of the effector 
molecules perforin and granzyme B or indirectly by producing IFN-γ38. In the later stages of 
infection, the majority of CTLs die and a small proportion become long-lived memory CD8+ T 
cells. SAY SOMETHING ABOUT NEEDING TO EXPAND A SMALL NUMBER OF VIRUS-
SPECIFIC CTLS DURING PRIMING. DO YOU WANT TO INTRODUCE THE 
IMMUNODOMINANT ANTIGEN IDEAS HERE? 
 Intriguingly, CD8+ T cells alone appear to provide incomplete protection against some 
orthopoxviruses and the role of CD8+ T cells in orthopoxvirus immunity was somewhat 
controversial. For instance, survival following ECTV challenge was demonstrated to be 
completely dependent on CD8+ T cells as CD8+ T cell depletion resulted in 100% mortality in 
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comparison to CD8+ T cell non-depleted controls39. Conversely, depletion of CD8+ T cells 
during lethal CPXV infection had no effects on mortality31,36. Similarly, depletion of CD8+ T 
cells during VACV infection had modest effects on viral clearance40,41, and instead CD4+ T cells 
and B cells largely mediated protection40. Nevertheless, CD8+ T cells were important for 
controlling VACV infection in the absence of CD4+ T cells and B cells40. 
 B cells contribute to viral immunity through the production of protective antibodies. The 
surface antibodies on B cells serve as the B cell antigen receptor (BCR). Upon encountering 
antigen, the BCR delivers the antigen for processing through the MHCII pathway. The antigen 
peptide-MHC class II (pMHCII) complexes can then be presented to and recognized by CD4+ T 
cells sharing the same antigen specificity42. CD4+ T cell-B cell interactions stimulates the 
production of molecules that differentiate B cells into antibody-secreting plasma cells43. The 
elicited antibodies can then limit the spread of virus by blocking virion attachment to cells. 
Virions or infected cells bound by antibodies can also be opsonized by the complement system, 
resulting in phagocytosis or killing of infected cells and virions44. Studies using ECTV and 
VACV demonstrate a critical role for B cells and CD4+ T cells, where deficiencies in either cell 
types results in death following viral challenge40,45,46, despite the mounting of a normal CD8+ T 
cell response. CD8+ T cell responses can however complement CD4+ T cell and B cell responses 
during orthopoxvirus infection40,45. 
Orthopoxvirus evasion of adaptive immunity  
 Given the importance of T and B cells in immunity against orthopoxviruses, it is no 
surprise that orthopoxviruses have evolved mechanisms to thwart the function of these adaptive 
immune cells. One such mechanism is to prevent the complement system from activating. 
VACV encodes a complement binding protein called vaccinia complement-control protein 
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(VCP). VCP prevents complement proteins from acting on antigen-bound antibodies47. Skin 
infection with VCP deficient VACV results in reduced lesion size in comparison to infection 
with VCP sufficient VACV48. Therefore, VCP is a virulence factor that indirectly inhibits 
antiviral antibodies produced by B cells.  
 Other mechanisms to evade B cell and CD4+ T cell functions have been reported, yet the 
in vivo relevance remains to be determined. For instance, MPXV and CPXV encode an 
orthopoxvirus MHC class I-like protein (OMCP) that binds to an immunoregulatory receptor 
expressed on B cells. These findings strongly suggest a role for OMCP in evading B cell 
responses49. Additionally, B cell MHCII antigen presentation to CD4+ T cells can be inhibited 
when B cells are infected with VACV50, implying that VACV may also prevent CD4+ T cell-B 
cell interactions in vivo. MPXV also encodes an immunoevasin that effectively suppresses both 
CD4+ T cell and CD8+ T cell stimulation, although MPXV does not inhibit MHCII and MHCI 
antigen presentation51. 
 While many viruses target antigen processing and presentation through the MHCI 
pathway in order to evade anti-viral CTLs, CPXV is the only orthopoxvirus capable of doing 
so31,36,52,53. There are two CPXV encoded proteins that inhibit MHCI antigen presentation, 
CPXV203 and CPXV012. CPXV012 prevents MHCI molecules from being loaded with antigen 
by binding to transporter associated with antigen processing (TAP) molecules, whereas 
CPXV203 binds to and retains MHCI in the ER of infected cells52,53. The combined functions of 
CPXV203 and CPXV012 effectively prevent CPXV-specific CTLs from recognizing infected 
target cells, resulting in significant consequences in vivo.  
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Investigating the effects of viral MHCI evasion on CD8+ T cell effector function and 
development. 
 CPXV-mediated MHCI inhibition effectively evades CPXV-specific CTL effector 
functions, but does not affect priming of naïve CPXV-specific CTL precursors. Direct priming is 
likely abrogated since CPXV-infected APCs are also subjected to CPXV-mediated MHCI 
inhibition53. However, following CPXV infection, CD8α+/CD103+ dendritic cells (BATF3+ DCs) 
prime naïve CTL precursors, suggesting that the induction of anti-CPXV CTL responses is 
dependent on cross-presenting BATF3+ DCs subsets31,36. Although BATF3+ DCs induce a strong 
anti-CPXV CTL response, CPXV-specific CTLs alone are ineffective at controlling CPXV 
infection and depletion of CD8+ T cells has no effects on mortality or survival during lethal 
CPXV infection31,36,52. Strikingly, infection with a CPXV mutant lacking the endogenous viral 
MHCI inhibitors (Δ12Δ203) induces a CTL response that is also dependent on BATF3+ DCs, but 
Δ12Δ203 is significantly attenuated in vivo in comparison to WT CPXV. In the absence of 
CPXV012 and CPXV203, CTLs are critical in viral clearance since mice depleted of CD8+ T 
cells succumb to infection with Δ12Δ203. Furthermore, in the absence of CD4+ T cells and B 
cells, CPXV-specific CTLs are sufficient in providing protection against Δ12Δ203, but not WT 
CPXV31.  
 Interestingly, infection with both WT CPXV and Δ12Δ203 results in local CTL response 
dominated by the viral epitope B819-26, which is restricted to the H-2Kb MHCI allomorph31. This 
phenomenon, known as immunodominance, has been investigated using VACV54–57. However, 
VACV does not inhibit MHCI antigen presentation58. Therefore, the determinants of 
immunodominance have not been thoroughly interrogated in a context where viral MHCI 
inhibition has significant consequences in vivo. Likewise, the effects of viral MHCI inhibition on 
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immunodominance within the memory CD8+ T cell pool, memory CD8+ T cell development in 
general, and memory CD8+ T cell effector functions remain unclear.  
 To address these issues, I compared primary CD8+ T cell and memory CD8+ T cell 
responses against WT CPXV infection to the respective responses against Δ12Δ203 infection. In 
chapter 2, I present my study on CD8+ T cell immunodominance during CPXV infection and 
discuss the factors that influence immunodominance in the presence of viral MHCI inhibition. I 
then present my study on memory CD8+ T cell formation/responses following CPXV infection 
and discuss the effects of viral MHCI inhibition on these processes in chapter 3. Finally, in 
chapter 4, I discuss the implications of these findings and additional questions that stem from my 
studies.    
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Chapter 2:  
Cross-priming induces immunodomination in 
the presence of viral MHC class I inhibition 
 
This chapter was published as a research article in PLOS Pathogens (2018). 
 
Authors: Elvin J. Lauron1, Liping Yang1, Jabari I. Elliott2, Maria D. Gainey3, Daved H. 
Fremont2,4,5, Wayne M. Yokoyama6,* 
 
1Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, 
United States of America, 2Department of Pathology and Immunology, Washington University 
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Western Carolina University, Cullowhee, North Carolina, United States of America, 
4Department of Biochemistry and Molecular Biophysics, Washington University School of 
Medicine, St. Louis, Missouri, United States of America, 5Department of Molecular 
Microbiology, Washington University School of Medicine, St. Louis, Missouri, United States of 
America, 6Division of Rheumatology, Washington University School of Medicine, St. Louis, 
Missouri, United States of America 
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Abstract 
Viruses have evolved mechanisms of MHCI inhibition in order to evade recognition by cytotoxic 
CD8+ T cells (CTLs), which is well-illustrated by our prior studies on cowpox virus (CPXV) that 
encodes potent MHCI inhibitors. Deletion of CPXV viral MHCI inhibitors markedly attenuated 
in vivo infection due to effects on CTL effector function, not priming. However, the CTL 
response to CPXV in C57BL/6 mice is dominated by a single peptide antigen presented by H-
2Kb. Here we evaluated the effect of viral MHCI inhibition on immunodominant (IDE) and 
subdominant epitopes (SDE) as this has not been thoroughly examined. We found that cross-
priming, but not cross-dressing, is the main mechanism driving IDE and SDE CTL responses 
following CPXV infection. Secretion of the immunodominant antigen was not required for 
immunodominance. Instead, immunodominance was caused by CTL interference, known as 
immunodomination. Both immunodomination and cross-priming of SDEs were not affected by 
MHCI inhibition. SDE-specific CTLs were also capable of exerting immunodomination during 
primary and secondary responses, which was in part dependent on antigen abundance. 
Furthermore, CTL responses directed solely against SDEs protected against lethal CPXV 
infection, but only in the absence of the CPXV MHCI inhibitors. Thus, both SDE and IDE 
responses can contribute to protective immunity against poxviruses, implying that these 
principles apply to poxvirus-based vaccines.  
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Introduction 
Strategies to leverage strong CD8+ cytotoxic T lymphocyte (CTL) responses to viral 
infections are of particular interest as CTLs play essential roles in controlling viral infections 
31,52,59–61. Before gaining effector functions, virus-specific CTL precursors must be primed by 
antigen presenting cells (APCs) that present pathogen-derived epitopes via major 
histocompatibility complex class I (MHCI) molecules on the cell surface. If the APC is infected 
and directly presents endogenously produced antigens, this is known as direct presentation. 
Alternatively, uninfected APCs may process and cross-present exogenous antigens from infected 
cells. Cross-presentation is mediated primarily by Batf3-dependent CD103+/CD8α+ dendritic 
cells (DCs) 62–64, which we refer to as BATF3+ DCs. Peptide-loaded MHCI molecules from 
infected cells may also be liberated by cell lysis or secreted in exosomes and then transferred 
onto cross-presenting APCs. When uninfected APCs acquire preformed peptide-MHCI 
complexes in this manner, they are termed cross-dressed and can drive expansion of CD8+ T 
cells 65–67. Induction of CD8+ T cell responses by cross-dressing was previously demonstrated in 
studies using adoptive transfer of T cell receptor (TCR) transgenic (Tg) T cells 65–67 and also 
requires BATF3+ DCs 67. However, the relative contribution of these processes to non-TCR Tg 
CTL responses against viral antigens is largely unknown. 
Upon recognizing cognate antigen on APCs, naïve CTLs are activated to undergo clonal 
expansion and traffic to the site of ongoing viral infection. There, virus-specific CTLs mediate 
host resistance by recognizing infected cells via surface MHCI molecules displaying processed 
viral antigens. Specific T cell recognition activates direct killing of infected cells and production 
of interferon-gamma (IFN-γ) and other cytokines that may have indirect effects. In the later 
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stages of the response, a proportion of CTLs become long-lived memory CD8+ T cells that can 
provide rapid protection during secondary responses to the viral pathogens. 
Many viruses display mechanisms that may contribute to evading CTL responses, such as 
inhibiting MHCI antigen presentation. The effects and mechanisms of MHCI inhibition on CTL 
responses have been well demonstrated in vitro with herpesviruses 68. For instance, 
downregulation of MHCI by murine cytomegalovirus (MCMV) prevented MCMV-specific 
CTLs from killing infected cells, whereas cells infected with an MCMV mutant lacking the viral 
MHCI inhibitors were lysed by CTLs 69. However, the in vivo relevance of viral MHCI 
inhibition in general was previously unclear since herpesvirus-mediated MHCI inhibition had 
few effects on in vivo CTL responses in murine and nonhuman primate infection models 70–72.   
On the other hand, studies of cowpox virus (CPXV) by our lab and others indicated that 
CPXV, uniquely among the orthopoxviruses, mediated mouse and human MHCI inhibition by 
two open reading frames (ORFs), CPXV012 and CPXV203 52,53,73. CPXV203 retains MHCI 
molecules in the ER and CPXV012 inhibits peptide loading on MHCI molecules; when 
combined, these two evasion mechanisms allows CPXV to evade CTL responses. The deletion 
of intact CPXV012 and CPXV203 from the CPXV genome attenuated viral pathogenesis in vivo 
31,52. Furthermore, this attenuation was dependent on the anti-CPXV CTL response since 
depleting CD8+ T cells restored the virulence of the Δ12Δ203 CPXV mutant, similar to wild type 
(WT) CPXV. Thus, these studies of CPXV established the in vivo importance of viral MHCI 
inhibition and its effects on antiviral CTL responses.  
Interestingly, the virus-specific CTL response to CPXV in C57BL/6 mice is dominated 
by a single antigen (B8), displaying the immunological phenomenon known as 
immunodominance, that can impede the development of efficacious vaccines 74. In theory, 
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removing the IDE(s) may circumvent immunity. However, for some viruses, subdominant 
epitopes (SDEs) may compensate and then dominate the immune response 35,75. Such findings 
revealed that responses against an IDE(s) suppress immune responses to SDEs, which is a related 
yet distinct phenomenon coined immunodomination. CD8+ T cell immunodomination also 
occurs during secondary responses whereby memory CD8+ T cells can suppress naïve CD8+ T 
cell responses 54. CD8+ T cell immunodomination is likely a mechanism that contributes to the 
immunodominance of the B8 antigen in CPXV infections 55, but has not been studied in the 
context of MHCI inhibition. 
B8R is a highly conserved gene among orthopoxviruses and encodes the secreted soluble 
B8 protein that binds IFN-γ with broad species-specificity. B8 from ectromelia virus (ECTV) is a 
strong inhibitor of human, bovine, rat, and murine IFN-γ 34, but VACV and CPXV B8 does not 
neutralize murine IFN-γ 76. These differences have been attributed to host-specificity. While the 
natural host of ECTV is not known, experimentally it is restricted to murine hosts, whereas 
VACV has a broad host-tropism with an unknown natural reservoir 77. The natural reservoirs of 
CPXV are wild-rodent species, but CPXV also has broad host-tropism 78,79. Despite these 
differences, B8 is the most dominant antigen identified in mice with the H-2Kb MHCI allele, and 
the B8 CD8+ T cell epitope sequence (TSYKFESV) is 100% conserved between ECTV, VACV, 
CPXV, and other orthopoxviruses 37. However, it is not clear if B8 is an immunodominant 
antigen because it is a secreted soluble protein that may be efficiently cross-presented. 
Previously, we showed that CPXV infection of Batf3-/- mice that selectively lack the main 
cross-presenting DC subsets (CD103+/CD8α+ DCs) 80 display reduced priming of B819-26-specific 
CD8+ T cells during CPXV infection 31, suggesting that cross-presentation is a major pathway 
used to induce CTLs. However, since Batf3–/– mice also lack the capability of cross-dressing, it is 
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also possible that cross-dressing is the main pathway to induce CPXV-specific CTLs. Moreover, 
it remained unclear whether other CPXV antigens (i.e., SDEs) are efficiently presented by 
BATF3+ DCs because CPXV B819-26 immunodominates the primary CTL response 31. Finally, 
due to the above limitations, it is not known if these processes could be affected by viral MHCI 
inhibition.  
Here we studied if transmembrane anchoring of B8 affects its immunodominance, the 
role of MHCI inhibition in the generation of virus-specific CTLs to SDEs and for the first time, 
the relevance of cross-dressing in the induction of endogenous antiviral CTL responses. 
 
Results 
Secretion of the immunodominant antigen is not a determinant for immunodominance 
The immunodominant CPXV B8 antigen is a secreted soluble protein 34, suggesting that 
its immunodominance may be due to its property as a secreted molecule, as shown for other 
antigens 81,82. If this were true, we expect that altering the protein targeting of B8 so that it is no 
longer secreted from infected cells will affect the acquisition and availability of B8 for APCs, 
which in turn would affect priming of B819-26-specific CD8+ T cells and its immunodominance. 
To test these hypotheses and detect subcellular location of B8, we produced a CPXV mutant 
expressing B8 fused to mCherry (B8mC) and another mutant (B8TMmC) expressing B8-
mCherry fusion protein with a transmembrane domain (TMD) (Fig 2.1A).  
We performed subcellular fractionation of infected HeLa cells and analyzed the 
cytoplasmic extract, membrane extract, and supernatant by Western blot to determine the 
subcellular location of the B8 variants and if they were secreted. The B8 variants were mainly 
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detected in the membrane extract of both B8TMmC- and B8mC-infected cells, indicating that the 
infected cells successfully expressed both B8 variants (Fig 2.1B). We note that the membrane 
fraction may contain proteins found within the mitochondria and endoplasmic reticulum, but not 
nuclear proteins, such that the secreted B8 variant detected in the membrane fraction is likely due 
to proteins localized within the ER and in transit through the secretory pathway. We also 
detected higher levels of the non-secreted B8 variant in the membrane fraction in comparison to 
the secreted variant, which is likely due to an accumulation of membrane-associated B8 within 
B8TMmC-infected cells. Most importantly, the B8 variant was detected in the supernatant of 
cells infected with B8mC, but not in the supernatant of cells infected with B8TMmC, 
demonstrating that the B8 variant remains cell-associated in cells infected with B8TMmC (Fig 
2.1B). However, anchoring the B8 antigen did not negatively affect priming of B819-26-specific 
CD8+ T cells and B819-26 maintained the highest position in the immunodominance hierarchy, as 
shown in mice infected intranasally (i.n.) with B8TMmC or B8mC (Fig 2.1C and 2.1D). These 
data show that secretion of the B8 antigen is not required for priming of B819-26-specific CD8+ T 
cells or immunodominance during CPXV infection.  
We also performed kinetic analyses of B819-26-specific CD8+ T cells by staining with 
H2Kb tetramers loaded with B819-26 peptide and found that priming by cell-associated B8 
resulted in greater expansion of B819-26-specific CD8+ T cells (Fig 2.1E). These results are 
consistent with previous findings that cell-associated antigens are cross-presented better than 
soluble antigens 83,84. When we infected Batf3-/- mice with B8TMmC or B8TM, we found that 
priming of B819-26 -specific CD8+ T cells was significantly reduced in Batf3-/- mice in 
comparison to B6 mice (Fig 2.1F), indicating that the introduced B8 mutations did not alter the 
dependence on cross-presentation (or cross-dressing) in the induction of B819-26-specific CTL 
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precursors. Since priming against the non-secreted B8 protein is still dependent on cross-
presenting (or cross-dressed) BATF3+ DCs, it is likely that antigens used for conventional cross-
presentation by BATF3+ DCs are acquired from infected apoptotic/necrotic donor cells or that 
BATF3+ DCs are cross-dressed with peptide-loaded MHCI molecules.  
 
Cross-presentation, but not cross-dressing of APCs, drives CTL responses during CPXV 
infection 
While we previously reported that priming of CD8+ T cell responses to CPXV is 
dependent on cross-presenting BATF3+ DCs, others reported that direct priming is the main 
mechanism to induce CTL responses with VACV infection 85,86. To directly compare these 
findings, we assessed the CTL response after systemic infection with WT CPXV, Δ12Δ203 
(from here on referred to as ΔMHCIi) CPXV, or VACV in B6 and Batf3-deficient mice. At 8 
days post-infection (dpi), the frequency of splenic CD8+ T cells that produced IFN-γ in ex vivo 
stimulations with ΔMHCIi-infected DC2.4 cells was significantly reduced in WT CPXV- and 
ΔMHCIi-infected Batf3-/- mice (Fig 2.2A) in comparison to infected B6 mice, confirming the 
importance of cross-presentation (or cross-dressing) in inducing CPXV-specific CTLs, as we 
showed earlier 31. Conversely, at 6 or 8 dpi, ex vivo stimulation with a set of 5 VACV/CPXV 
peptides (Fig 2.2B) or VACV-infected DC2.4 (Fig 2.2A) revealed no significant difference in the 
VACV-specific response between infected B6 and Batf3-/- mice. These results are consistent with 
the findings that ablation of XCR1-expressing (CD103+/CD8α+) DCs does not completely 
abolish priming of CD8+ T cells during VACV infection 87. Thus, the in vivo responses to two 
highly related orthopoxviruses display distinct requirements for direct presentation (VACV) 
versus cross-presentation/cross-dressing (CPXV). 
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Given that priming of CPXV-specific CTL precursors and cross-dressing of APCs in 
other settings were both shown to require BATF3+ DCs 67, we sought to determine if cross-
dressing could account for the source of antigen being presented to CD8+ T cells in CPXV 
infection. To do so, we transferred B6 bone marrow into lethally irradiated Batf3-/--F1 (Batf3-/--
B6 x Batf3-/--BALB/c) mice (Fig 2.3A). In B6àBatf3-/--F1 chimeras, donor B6-derived (Batf3-
dependent) APCs only express H-2b MHCI molecules and should cross-prime CTL responses 
against H2b-restricted epitopes (Fig 2.3A). However, priming by H-2d-restricted epitopes would 
occur only if the H2b APCs in these chimeric mice were cross-dressed with preformed peptide-
loaded H-2d class I molecules from the host parenchymal cells, which express both H-2b and H-
2d class I molecules. We also produced BALB/càBatf3-/--F1 chimeras, to analyze the converse 
situation. The reconstituted mice were infected by i.n. administration with WT CPXV and CTL 
responses were determined against the immunodominant H-2Kb-restricted B819-26 and the H-2Ld-
restricted F226-34 epitopes. As expected, we detected a B819-26 response in B6àBatf3-/--F1 mice 
that was of similar magnitude to non-chimeric WT-F1 (B6 x BALB/c) infected mice (Fig 2.3B). 
We also detected a small B819-26-specific response in BALB/càBatf3-/--F1, but the frequency of 
B819-26-specific CD8+ T cells was significantly lower (~12-fold) than in B6àBatf3-/--F1 and WT-
F1 mice. A small, yet detectable response to F226-34 was also detected in the lungs of B6àBatf3-/-
-F1-infected mice, but it was ~3 fold and ~8 fold lower in comparison to WT-F1- and 
BALB/càBatf3-/--F1-infected mice respectively. Thus, these data suggest cross-dressing 
contributes minimally to priming against these peptide determinants.  
It is possible that cross-dressing by H-2Kb- and H-2Ld-restricted epitopes other than B819-
26 and F226-34, respectively, occurred in infected BMC mice, so we also performed ex vivo 
stimulations with ΔMHCIi-infected DC2.4 (H-2b) and P815 (H-2d) cells as these cells present a 
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broad array of naturally derived CPXV peptides (Fig 2.3B). The frequency of IFN-γ+ CD8+ T 
cells upon stimulation with ΔMHCIi-infected DC2.4 cells was significantly lower in 
BALB/càBatf3-/--F1 mice in comparison to B6àBatf3-/--F1 and WT-F1 mice. Similarly, the 
frequency of IFN-γ+ CD8+ T cells upon stimulation with ΔMHCIi-infected P815 cells was 
significantly lower in B6àBatf3-/--F1 mice in comparison to BALB/càBatf3-/--F1 and ~10 fold 
lower in comparison WT-F1 mice. The frequency of CD8+ T cells that responded to ΔMHCIi-
infected P815 cells was also significantly lower in WT-F1 in comparison to BALB/càBatf3-/--F1. 
This was also seen in F226-34 responses (Fig 2.3B). These findings may be due to the additional 
epitope diversity from H-2b as well as H-2d expression in WT-F1, which may compromise 
responses to H-2d-restricted epitopes during the primary response. Regardless, these results 
suggest that cross-dressing from non-hematopoietic cells does not generate a vigorous response 
during primary CPXV responses.  
We next assessed whether cross-dressing plays a role during secondary responses to 
CPXV infection since cross-dressed APCs are capable of stimulating memory CD8+ T cells 65. 
However, the secondary CPXV response in the B6àBatf3-/--F1 and BALB/càBatf3-/--F1 mice 
were similar to what was observed in the primary CPXV response (Fig 2.3C). Thus, cross-
dressing from non-hematopoietic cells also plays a minor role in activating endogenous memory 
CD8+ T cells following CPXV infection.  
 To test if cross-dressed MHCI could be contributed by the hematopoietic compartment, 
we reconstituted lethally irradiated Batf3-/--F1 mice with a 1:1 mixture of BALB/c-Thy1.1 and 
Batf3-/--F1 bone marrow (S2.1A Fig). In these mice, cross-presentation should only be carried out 
by the donor BALB/c-Thy1.1-derived APCs (H-2d). In contrast, cells that are of the donor Batf3-
/--F1 (H-2b x H-2d) origin will lack BATF3+ DCs and should not carry out cross-presentation, but 
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may serve as a source of cross-dressing peptide-MHCI complexes. We systemically infected 
BALB/c-Thy1.1 + Batf3-/--F1àBatf3-/--F1 mice with WT CPXV and found that the H-2d-
restricted response was successfully reconstituted, whereas the H-2b-restricted response was 
significantly lower than the response in WT-F1 mice and was comparable to Batf3-/--F1àBatf3-/--
F1 control mice (S2.1B Fig). These data indicate that APCs cross-dressed from other 
hematopoietic cells does not efficiently prime CD8+ T cell responses in the setting of effective 
viral MHCI inhibition.  
Taken together, these data suggest that antigens are predominantly cross-presented by 
BATF3+ DCs during CPXV infection and that cross-dressing plays a minor role, if at all.  
 
Cross-presentation of SDEs in the absence of the IDE induces a robust CD8+ T cell 
response that is not affected by viral MHCI inhibition, revealing immunodomination  
Insufficient cross-presentation of SDEs may explain the subdominance of other CPXV 
antigens. To test if cross-presentation of CPXV SDEs alone is capable of inducing a strong CTL 
response, we mutated the B819-26 epitope anchor residues required for binding to H-2Kb peptide-
binding groove, postulating that this will prevent the B819-26 epitope from being presented by H-
2Kb. According to the peptide-binding motif of H-2Kb, the B819-26 epitope contains a primary 
anchor residue (phenylalanine at position P5) and an auxiliary anchor residue (tyrosine at 
position P3) 88. To determine whether mutating the primary anchor residue is sufficient to 
eliminate binding to H-2Kb or if both anchor residues should be mutated, peptide-binding assays 
were performed using the transporter associated with antigen processing 2 (TAP2)-deficient 
RMA-S cell line in which addition of peptides capable of binding H-2Kb stabilize its expression 
on the cell surface 89. Alanine substitution of the primary anchor residue significantly reduced 
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binding of the B819-26 epitope peptide to H-2Kb as compared to WT B8, but binding could be 
increased with increasing concentrations of peptide (S2.2A Fig). However, alanine substitutions 
of the primary and auxiliary anchor residues completely abrogated binding of the B819-26 epitope 
peptide to H-2Kb, even at higher peptide concentrations. Based on these findings, we introduced 
both substitutions into the WT and the ΔMHCIi CPXV genomes. The CPXV B819-26 epitope 
mutants B8Y3AF5A (referred to as ΔB819-26) and a B8R deletion mutant (ΔB8R) that we 
generated did not exhibit defects in viral replication in vitro (S2.2B Fig). Surprisingly, they also 
did not show attenuated virulence in vivo, as measured by weight loss or lethality, as compared 
to WT CPXV (S2.2C Fig). 
There was no detectable B819-26 response in ΔB819-26- or ΔMHCIiΔB819-26-infected mice 
(Fig 2.4A and 2.4B, S2.3A and S2.3B Fig). However, infections with ΔB819-26 or ΔMHCIi-
ΔB819-26 generated a robust SDE response. In contrast, as we previously reported 31, a large 
proportion of the CPXV-specific CTL response was directed against B819-26 in the lungs of WT- 
and ΔMHCIi-infected mice. Additionally, there were no significant differences between the 
overall CTL responses against WT, ΔB819-26, ΔMHCIi, and ΔMHCIiΔB819-26  (Figs 2.4A and 
2.4B), despite the loss of the B819-26-specific response. Therefore, the CTL response was 
completely compensated by SDEs in the absence of a B819-26 response.  
It was possible that the B819-26 epitope mutation allows CPXV to replicate to higher titers 
in the lungs of infected mice resulting in higher antigen loads, which could explain the observed 
compensation. However, the B819-26 epitope mutations did not result in significantly increased 
viral titers in infected mice (Fig 2.4C), suggesting that the compensation is unlikely due to 
increased antigen loads. 
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Immunodomination and priming by SDEs were also not affected by CPXV-mediated 
MHCI inhibition since there were no significant difference in the SDE response against ΔB819-26 
and ΔMHCIiΔB819-26, as measured by stimulation with ΔMHCIi- (used to estimate total 
response) or ΔMHCIiΔB819-26- (used to estimate total SDE response) infected DC2.4 cells (Fig 
2.4A and 2.4B). Additionally, there was no significant difference in the frequency of CD8+ T 
cells that exhibited an effector T cell phenotype in infected mice (S2.3C and S2.3D Fig). 
Considering that the route of infection can alter antigen levels and immunodominance 55, we 
infected mice by intraperitoneal (i.p.) injections. Compensation by SDEs was also observed 
during systemic infection (Figs 2.4D and 2.4E), suggesting that compensation was not dependent 
on antigen levels or the route of infection. However, CTL responses against the panel of 
subdominant epitopes we tested were not significantly increased in the absence of B819-26, 
suggesting that other unidentified or cryptic subdominant epitopes compensated the CTL 
response. Interestingly, the response against A4288-96 was significantly reduced in the absence of 
the B819-26-specific response (Fig 2.4D), suggesting that SDEs were up-ranked in the dominance 
hierarchy and were now themselves eliciting immunodomination. Furthermore, we found that 
priming of SDE-specific CD8+ T cells was also dependent on BATF3+ DCs (S2.3E Fig). These 
data suggest that the IDE-specific CTL response suppresses cross-priming of SDE-specific CD8+ 
T cells during primary CPXV infections, indicating immunodomination, but this process was not 
affected by viral MHCI inhibition.  
 
SDE-specific CD8+ T cell are effective at immunodomination during primary and 
secondary CPXV infection 
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Memory CD8+ T cells also have a capacity for immunodomination and can inhibit naïve 
CD8+ T cell responses 54. However, this is not the case for VACV since prior priming with 
individual SDEs does not alter the immunodominance hierarchy following VACV boost in SDE-
primed mice 56. Considering that the priming mechanisms are different during VACV and CPXV 
infection (Fig 2.2A), we tested whether CPXV-specific memory CD8+ T cells can exert 
immunodomination. We primed mice with WT CPXV, boosted the mice with a low or high dose 
of ΔB819-26 at 25 dpi, and assessed the CD8+ T cell response in the lungs and spleens 8 days after 
boosting (Fig 2.5A). In this group, B819-26-specific memory CD8+ T cells should be present pre- 
and post-boost, but will not undergo expansion following boost with ΔB819-26. As expected, we 
detected B819-26-specific CD8+ T cells in the lungs and spleens of WT CPXV-primed mice after 
boosting with ΔB819-26  (Fig 2.5B and 2.5C) and before boosting (Fig 2.5D). Additionally, we 
found that WT and ΔMHCIi infection resulted in a similar relative abundance of B819-26-specific 
CD8+ T cells with a memory phenotype (CD44+CD62L+KLRG1-CD127+) at 25 dpi, suggesting 
that viral MHCI inhibition does not affect memory T cell development (Fig 2.S4). In a separate 
group, mice were primed with SDEs by ΔB819-26 infection and boosted with WT CPXV. In this 
group, we would expect mice to mount a naïve B819-26 response after boosting with WT CPXV 
only in the absence of memory CD8+ T cell immunodomination. However, the naïve B819-26 
response was significantly inhibited following boost with both a low and high dose of WT 
CPXV, suggesting that the SDE-specific memory CD8+ T cells immunodominate naïve CD8+ T 
cells. Alternatively, neutralizing antibodies may have reduced the antigen levels and therefore 
limited the naïve B819-26 response following boost with CPXV.  
To assess the potential role of host-protective antibodies, we repeated the above 
experiments, but this time we depleted CD8+ T cells prior to challenging mice with CPXV 
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(S2.5A and S2.5B Fig) and then monitored the mice for survival. CPXV-immunized mice that 
received CD8-depleting or isotype control antibodies survived, whereas naïve mice succumbed 
to the challenge (S2.5C Fig). Although this was somewhat expected because CPXV evades 
CTLs, these results suggest that host-protective antibodies may contribute to protection in the 
absence of CD8+ T cells during secondary exposure to CPXV. We thus repeated the prime and 
boost experiments and examined immunodomination in µmT mice, which lack mature B cells. 
Because CPXV evades CTLs in vivo and µmT mice should not mount a protective antibody 
response, it is likely that µmT mice are highly susceptible to WT CPXV infection. To avoid this 
issue, we infected µmT mice with ΔMHCIi CPXV strains as CTLs can effectively control these 
viruses in WT mice. We primed µmT mice by skin scarification (s.s.) infection, which resembles 
human immunizations with VACV. We then boosted the mice at 25 dpi by i.n. administration, 
and subsequently assessed the CD8+ T cell response 7 days after boost. Mice primed with 
ΔMHCIi resulted in expansion of a B819-26-specific CD8+ T cells following i.n. boost with 
ΔMHCIi (Fig 2.5E). Mice primed with ΔMHCIiΔB819-26 also mounted a detectable response 
against B819-26 following i.n. boost with ΔMHCIi, yet this response was significantly reduced by 
~9-fold in comparison to mice immunized with ΔMHCIi. Therefore, memory CD8+ T cell 
immunodomination still occurred in the absence of neutralizing antibodies and viral MHCI 
inhibition, suggesting that immunodomination may be due to T cell interference. 
Because memory CD8+ T cells are present at higher frequencies than naïve antigen-
specific CD8+ T cells, it is likely that memory CD8+ T cells have a competitive advantage in 
accessing APC resources 90–92. For instance, downregulation of MHCI on infected cells may 
limit the level of antigen presented during CPXV infection, thereby contributing to T cell cross-
competition for peptide-MHCI complexes in the secondary response. Indeed, T cell cross-
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competition for peptide-MHCI complexes during secondary responses has been demonstrated 
using a heterologous prime-boost strategy 93, but to our knowledge this has only been directly 
tested between memory and naïve T cells specific for IDEs. To test if SDE-specific memory 
CD8+ T cells can cross-compete with naïve B819-26-specific CD8+ T cells, we performed a 
competition experiment in which we primed mice with ΔB819-26, adoptively transferred peptide-
pulsed BMDCs at 25 dpi, and then assessed the CD8+ T cells responses 6 days after transfer. 
Transfer of B819-26-pulsed BMDCs into ΔB819-26 -primed mice resulted in a robust B819-26 
response (Fig 2.5F). Likewise, transfer of K36-15-pulsed BMDCs resulted in moderate expansion 
of K36-15-specific memory CD8+ T cells. However, when BMDCs that were pulsed with B819-26 
and K36-15 at the same time were transferred the B819-26 response was inhibited, further 
supporting the findings that memory CD8+ T cells immunodominate naïve CD8+ T cells. 
Conversely, B819-26-specific CD8+ T cells dominated the response when BMDCs pulsed with 
B819-26 and K3L6-15 at the same time were transferred into naïve mice (Fig 2.5G). If 
immunodomination is an effect of cross-competition, then providing BMDCs that exclusively 
present K36-15 and BMDCs that exclusively present B819-26 alone should overcome the effects of 
immunodomination. When B819-26-pulsed BMDCs were mixed with K36-15-pulsed BMDCs 
(pulsed separately) and transferred into ΔB819-26-primed mice, the B819-26 response was 
significantly greater than in mice that received BMDCs pulsed with B819-26 and K3L6-15 at the 
same time, suggesting that cross-competition plays a role in memory CD8+ T cell 
immunodomination. 
Interestingly, the B819-26 response in mice that received the 1:1 mixture of K3L6-15-pulsed 
and B819-26-pulsed BMDCs was significantly lower than in mice that only received B819-26-
pulsed BMDCs. Therefore, the partial rescue of the B819-26 response when the epitopes were 
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presented on different APCs suggest that additional factors contribute to immunodomination 
during secondary responses. In contrast to the secondary response, separating the K36-15  and 
B819-26  epitopes during primary responses had no effect on immunodomination of B819-26-
specific CD8+ T cells (Fig 2.5G), suggesting that cross-competition for peptide-MHCI 
complexes contributes to immunodomination mainly during secondary responses. 
Having demonstrated that SDE-specific memory CD8+ T cells have a capacity for 
immunodomination, we asked if SDE-specific CD8+ T cells could exhibit immunodomination 
during primary responses. We reasoned that modulating the immunodominant and subdominant 
antigen levels may allow SDE-specific CD8+ T cells to immunodominate. To test this, we 
performed co-infection experiments in which the level of WT and ΔB819-26 input were varied 
while maintaining the overall viral dose. We first synchronized the infections to limit the 
variation in the dose by infecting freshly harvested splenocytes with either WT or ΔB819-26 
separately. We then mixed WT- and ΔB819-26-infected splenocytes at a ratio of 1:0, 10:1, 1:10, or 
0:1, inoculated mice i.v. with a total of 1 x 105 infected cells, and assessed the CTL response at 7 
dpi (Fig 2.6A). A graded B819-26 response was observed with the concurrent increase of ΔB819-26 
input and decrease of WT input (Fig 2.6B), while the overall response as determined by 
stimulation with ΔMHCIi-infected DC2.4 cells remained roughly equal (Fig 2.6C). These data 
suggest that SDE-specific CTLs are capable of immunodominating the primary response when 
the relative abundance of subdominant antigens is increased, even in the presence of the IDE. To 
confirm that the graded response was not simply due to reduced WT input, we repeated the co-
infection experiment using mixtures of WT- and mock-infected splenocytes. Injecting the 
varying mixtures of WT- and mock-infected splenocytes did not result in a gradation of the B819-
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26 response (Fig 2.6B), suggesting that the observed graded B819-26 response was dependent on 
the subdominant antigen levels.  
 
SDE-primed CD8+ T cells control lethal CPXV infection in the absence of the CPXV MHCI 
inhibitors 
  Thus far, our results indicate that CPXV-mediated MHCI inhibition does not affect 
priming of CD8+ T cells by SDEs. However, we wondered whether SDE-specific CTL responses 
could provide protection against CPXV infection in vivo. To examine the physiological 
relevance of SDEs in protecting against CPXV infection, we performed adoptive transfer 
experiments with CTLs primed with ΔB819-26 or MCMV as a control for antigen specificity (Fig 
2.7A). Mice that received primed CTLs were then challenged by i.n. administration with a lethal 
dose of ΔB819-26 or ΔMHCIiΔB819-26. The majority of mice that received MCMV-primed CTLs 
died following infection with ΔB819-26 or ΔMHCIiΔB819-26 (Fig 2.7B and 2.7C). All mice that 
received ΔB819-26-primed CTLs also died after challenge with ΔB819-26, whereas all mice 
challenged with ΔMHCIiΔB819-26 survived. Therefore, CTLs primed by SDEs are capable of 
recognizing and controlling CPXV only in the absence of CPXV-mediated MHCI inhibition, 
which is consistent with our previous findings regarding WT CPXV exposure that is dominated 
by the B819-26 response 31,52.  
 
Discussion 
Headings may be typed above or on the same line as the sections they label.  Type the 
chapter number and section number before the section title. The font size for section headings 
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should be no larger than 18. Here we demonstrate that the secretion of an immunodominant 
CPXV antigen does not affect immunodominance or cross-priming by the IDE. Intriguingly, we 
found that the IDE and SDEs are differentially presented by APCs during infection with CPXV 
and VACV, despite being closely related genetically. We also show that CD8+ T cell 
immunodomination is not affected by viral MHCI inhibition and can be elicited by SDEs during 
primary and secondary responses against CPXV infection. Additionally, we show that SDEs 
alone are entirely capable of generating protective CTL responses, which is dependent on cross-
priming by BATF3+ DCs. 
Cross-priming of CD8+ T cells is important for inducing antiviral CTL responses, 
especially in settings where direct-presentation is not possible (e.g., APCs are not susceptible to 
infection) or is evaded (e.g., impairing maturation of infected-APCs or inhibiting MHCI 
presentation). Consistent with this notion, herein we showed that the induction of antiviral CTL 
responses is dependent on cross-presentation in the presence of CPXV-mediated MHCI 
inhibition. Priming of CD8+ T cell in the absence of viral MHCI inhibition during CPXV 
infection was also dependent on cross-presenting BATF3+ DCs, albeit to a less extent. While we 
have not ruled out the possibility that ΔMHCIi-infected BATF3+ DCs prime CTL precursors by 
direct presentation, CPXV-infected DCs have reduced expression of costimulatory molecules 
involved in T cell activation 94,95, suggesting that direct-presentation may be limited even in the 
absence of CPXV012 and CPXV203. Nonetheless, there are clearly factors other than MHCI 
inhibition that skew priming of T cells towards cross-priming and further study of CPXV ORFs 
in the context of ΔMHCIi provides an excellent opportunity to investigate such factors. In this 
study, we provide evidence that cross-priming is the main mechanism driving CPXV-specific 
CTL responses. 
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Our studies also indicate that cross-dressing plays no significant role in the T cell 
response to CPXV infections in vivo. Cross-dressing has been proposed as a mechanism by 
which APCs can rapidly acquire peptide epitopes for presentation to CTL precursors, thereby 
eliminating the time spent for antigen processing 65,66. In support of this, DCs can be cross-
dressed in vitro by peptide-MHCI complexes from epithelial cells 96, which are commonly 
targeted by viruses and thus may serve as a common source of preformed viral peptide-MHCI. 
Moreover, peptide-MHCI from parenchymal cells cross-dressed DCs in vesicular stomatitis virus 
(VSV)-infected mice and the cross-dressed DCs induced proliferation of memory CD8+ T cells, 
but not naïve T cells. However, priming of naïve antigen-specific CD8+ T cells by cross-dressed 
DCs can occur, as demonstrated using DNA vaccination and transfer of adenovirus infected DCs 
66,67. In contrast to these studies, we found that cross-dressing does not efficiently prime or drive 
expansion of endogenous antigen-specific naïve and memory CD8+ T cells during CPXV 
infection.  
While previous reports on cross-dressing provide compelling evidence that cross-dressing 
occurs in vivo, the transfer of TCR tg T cells in these studies may have resulted in non-
physiological induction of CD8+ T cells by cross-dressed DCs. Additionally, cross-dressing in 
these experimental settings may have been promoted due to a potential generation of 
supraphysiological levels of peptide-MHCI by DNA vaccination or by transfer of adenovirus 
infected DCs. These factors may explain the difference between previous studies and our results 
using CPXV infection. Because CPXV encodes an extensive arsenal of immunomodulatory 
proteins, the possibility that CPXV directly or indirectly inhibits cross-dressing may also explain 
these conflicting results. For example, downregulation of MHCI cell surface expression by 
CPXV012 and CPXV203 may prevent transfer of peptide-loaded MHCI molecules by 
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trogocytosis, a process in which intercellular exchange of intact membranes occurs during the 
formation of an immunological synapse 97–100. If trogocytosis is required for cross-dressing of 
APCs in vivo, as been demonstrated in vitro 65, then cross-dressing dependent T cell responses 
are expected to be abrogated during CPXV infection. Ultimately, our results suggest that 
antigens are acquired from necrotic/apoptotic bodies or secreted viral proteins found in the 
extracellular milieu and are then predominantly cross-presented during CPXV infection. 
Cross-presentation of peptide epitopes may also be influenced by the nature of the 
antigens and can affect the extent of CD8+ T cell immunodominance 101–103. For instance, the 
secreted immunodominant antigens of M. tuberculosis are likely processed through the cross-
presentation pathway 104,105 and eliminating bacterial secretion prevents priming of IDE-specific 
CD8+ T cells during M. tuberculosis infection 81. Priming of naïve CD8+ T cells against cell-
associated subdominant SV40 large tumor antigen (T Ag) epitope V is also dependent on cross-
presentation, but the response against the V epitope is limited because it is inefficiently cross-
presented relative to the T Ag IDE 103. Our findings suggest that cross-presented CPXV IDEs can 
be derived from cell-associated antigen since ablating B8 secretion did not negatively affect 
cross-priming dependent induction of B819-26-specific CD8+ T cells. Moreover, cell-associated 
B8 elicited a greater B819-26-specific CD8+ T cell response in comparison to secreted soluble B8, 
which is consistent with the preferential in vivo cross-presentation previously reported for cell-
associated antigens 83,84. However, the underlying mechanisms of immunodominance are 
complex and are often context dependent as we found that secretion of CPXV B8 is not required 
for immunodominance and that cross-presentation of CPXV SDEs in the absence of the 
immunodominant B819-26 epitope stimulated a robust CTL response. The fact that the CTL 
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response to SDEs compensated for the absence of B819-26 suggests that the SDE response is 
suppressed by the B819-26 response, supporting the concept of immunodomination.  
In many cases immunodomination occurs as a consequence of T cell competition for 
limiting APC resources 90,92,106,107. For instance, competition for peptide-MHCI complexes on 
APCs during primary CTL responses can occur as a result of antigen abundance 108. In support of 
this, we showed that concurrently increasing subdominant antigen levels and reducing 
immunodominant antigen levels allow SDEs to gain dominance during the primary response to 
CPXV infection. Similarly, modulating the antigen abundance through different methods during 
influenza A virus and VACV infection has been shown to influence immunodomination 55,109. In 
certain models, immunodomination can be overcome when APCs present different epitopes 
separately 91,100,107, indicating that CD8+ T cells of different specificities can cross-compete for 
peptide-MHCI complexes on APCs. This has been convincingly demonstrated in models where 
immunodomination occurs when APCs co-present model antigen epitopes. However, epitope co-
presentation by APCs does not always influence immunodomination, as we have shown here for 
primary responses, and the role of cross-competition in inducing antiviral CTL responses is 
controversial 110.  
We found that cross-competition for peptide-MHCI complexes is relevant and that 
immunodomination occurs during secondary responses as a consequence. Alternatively, the 
suppressed B819-26 response in our cross-competition experiments may have resulted from K36-
15-specific memory CD8+ T cells killing the BMDCs that were pulsed with B819-26 and K3L6-15 at 
the same time. Nevertheless, we observed partial rescue of the B819-26 response when the 
epitopes were separated on BMDCs. This partial rescue may be due to peptide exchange between 
BMDCs that were pulsed separately and adoptively transferred as a mix, which would 
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subsequently result in epitope co-presentation and K36-15-specific memory CD8+ T cell 
immunodomination. However, additional factors that we did not test such as cross-competition 
for growth factors, antigen-specific T cell precursor frequencies, or TCR avidity 111 likely 
contribute to the memory T cell immunodomination as well. 
Remarkably, immunodomination during the secondary response against CPXV was 
exerted by SDE-specific memory CD8+ T cell. The capacity for SDE-specific memory CD8+ T 
cells to inhibit the response to an IDE has been shown with influenza virus 54, but prior priming 
with SDE peptides did not result in memory CD8+ T cell immunodomination using VACV, as 
shown by Wang et al 56. Here in our study, memory CD8+ T cell immunodomination was clearly 
evident when SDE-primed mice were challenged with WT CPXV, whereby the naïve B819-26-
specific CD8+ T cell response was suppressed. Moreover, memory CD8+ T cell 
immunodomination was not affected by MHCI inhibition. However, mice were primed by CPXV 
infection (in this study) as opposed to individual SDE peptides (as done by Wang et al). These 
experimental differences suggest that the priming stimulus and the breadth of the primary 
response influences immunodomination during secondary responses against poxviruses.  
Taken together, our findings highlight the need to consider the effects of pre-existing 
immunity on the outcome of secondary responses and vaccinations. An advantage to using 
VACV-based vaccines is that in addition to providing protection against heterologous pathogens, 
the native vector epitopes (both IDEs and SDEs) can provide cross-protection against related 
orthopoxviruses, as supported by our findings here and previous reports 112–115. However, as a 
consequence of pre-existing immunity, memory CD8+ T cell immunodomination may limit the 
target antigen response following immunization with VACV-based vaccines, in turn resulting in 
non-efficacious vaccinations. For example, native VACV epitopes can mask responses against 
 
 
34 
target antigens expressed by VACV vaccine vectors 74. Nevertheless, our results support the 
ongoing evaluation for poxviruses as promising vaccine vectors, and stress the necessity to 
develop novel vaccination strategies.  
 
Materials and Methods 
Cell lines, mice and viruses. 
Cell lines HeLa, Vero, and P815 were obtained from the American Type Culture Collection 
(ATCC). DC2.4 cells were a kind gift from Dr. Kenneth Rock, University of Massachusetts 
Medical School. HeLa, Vero, DC2.4, and P815 cells were cultured respectively in Dulbecco’s 
Modified Eagle Medium (DMEM), Minimum Essential Medium (MEM) or RPMI supplemented 
with 10% FBS (Mediatech), 100 U/ml penicillin, 100 g/ml streptomycin, 1mM sodium pyruvate, 
and non-essential amino acids (Gibco). VACV-WR was obtained from the ATCC. MCMV 
Smith strain was a gift from Dr. Herbert Virgin, Washington University. CPXV BAC pBR mini-
F construct was kindly provided by Dr. Karsten Tischer, Free University of Berlin. Mutant 
viruses were generated by en passant mutagenesis 116 using primers listed in S2.1 Table. Gene 
fragments were synthesized (Integrated DNA Technologies) and assembled using Gibson 
Assembly (New England BioLabs) for cloning of the B8-mCherry fusion contructs (S2.2 Table). 
Infectious BAC-derived viruses (S2.3 Table) were reconstituted using a slightly modified 
method previously described by Xu et al 117. In brief, ~8x105 Vero cells seeded in 6-well plates 
were infected with fowlpox virus (FWPV) at an MOI of 1. Transfection of FWPV-infected Vero 
cells was carried out 1 hour post-infection (hpi) with 4 µg of BAC DNA and 5 µL of 
Lipofectamine 2000 transfection reagent (ThermoFisher Scientific) according to the 
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manufacturer’s instruction. Serial dilutions of reconstituted infectious virus were passaged up to 
four times on Vero cells in order to remove the mini-F vector sequence. Wells harbouring single 
GFP-negative plaque were isolated and used for preparing virus stocks as previously described 
53. C57BL/6Ncr mice were purchased from the National Cancer Institute. B6.129S2-Ighmtm1Cgn/J 
mice were purchased from the Jackson Laboratory. Batf3-/- mice crossed to the C57BL/6 and 
BALB/c background were kindly provided by Dr. Kenneth Murphy, Washington University. 
Growth curves were performed on Vero cells. Supernatant and cells were harvested at 12, 24, 28, 
and 72 hpi and viral titers were determined by plaque assay using Vero cells.  
 
Peptide binding Assay 
TAP2-deficient RMA-S (H-2b) cells were cultured overnight at 28°C in 5% CO2 to accumulate 
peptide-receptive MHCI molecules at the cell surface. Peptides were then added at various 
concentrations and the cells were transferred to 37°C. After 6 h of incubation at 37°C, cells were 
harvested and washed twice in PBS. H-2Kb cell surface expression was then measured by flow 
cytometry. 
 
Western blot 
1 x 106 HeLa cells were infected at a MOI of 5. Cells and supernant were collected at 4 hpi and 
were lysed on ice for 5 min in RIPA lysis buffer supplemented with 1x Halt protease and 
phosphatase inhibitor cocktail. Cells were further processed for subcellular fractionation using a 
Subcellular Protein Fractionation Kit (ThermoFisher). Samples were mixed with Laemmli 
sample buffer (Bio-Rad), incubated at 95°C for 5 minutes, separated by SDS-PAGE, and 
transferred to PVDF membranes. Immunoblotting was performed using rabbit polyclonal anti-
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mCherry and rabbit monoclonal anti-EGFR (Abcam) followed by horseradish peroxidase (HRP)-
conjugated goat anti-rabbit IgG (Cell Signalling).  
 
Generation of bone marrow chimeras 
6 weeks of age Batf3-/--F1 (H2bxH2d) mice were depleted of NK cells by i.p. administration of 
100 µg of PK136 antibody. Two days later, the mice were lethally irradiated with 950 rads and 
were reconstituted with 1x107 T cell depleted C57BL/6, BALB/c, or a 1:1 mixture of BALB/c-
Thy1.1 and Batf3-/--F1 bone marrow cells. Bone marrow chimeras were treated with antibiotics 
for 4 weeks and were allowed to reconstitute for 8 weeks before use. 
 
Generation of bone marrow-derived DCs and immunization 
BM-derived dendritic cells (BMDCs) were generated by culturing BM cells in the presence of 20 
ng/mL GM-CSF and IL-4 (PeproTech) for 8 days, as previously described 118. LPS (150ng/nL) 
was then added and the cells were allowed to mature overnight. The cells were then pulsed with 
peptide (1g/mL, 45 min). Cells were washed extensively in PBS and a total of 2.5 x 105 DCs was 
injected intravenously (i.v.) into recipient mice.  
 
Mouse infection and CD8+ T cell adoptive transfer  
Mice were age- and sex-matched for each experiment and used at 8-10 weeks of age. Mice were 
infected as previously described for i.n. and s.s. infections 31. For s.s. infections, fur was trimmed 
with clippers, then a thin layer of Vaseline was applied over the trimmed region and the 
remaining fur was shaved over with a double-edge razor blade one day before infection. Mice 
infected by i.p. or s.c. administration were injected with a volume of 100µL or 200µL of virus 
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inoculum per mouse, respectively. For co-infection experiments, splenocytes isolated from B6 
mice were infected at an MOI of 5, harvested 1 hpi, and washed three times with PBS. 1 x 105 
infected cells in 200 µL of PBS were transferred intravenously into naïve B6 mice. For the 
CPXV SDE protection experiment, CD8+ T cells from splenocytes of infected B6 mice that had 
been infected 7 days earlier with WT CPXV or MCMV were isolated by positive selection using 
anti CD8a MicroBeads (Miltenyi Biotec). 3 x 106 CD8+ T cells were transferred intravenously 
into naïve B6 mice. Mice were infected approximately 24 h after transfer. 
 
Flow cytometry, IFN-γ production assays, and antibodies 
Single-cell suspensions from the lungs and spleens were prepared at the indicated days post-
infection as previously described 31. 1x106 cells were seeded in 96-well plates and were re-
stimulated with peptides or with 1x105 DC2.4 cells that had been infected for 4 h with ΔMHCI-i 
or ΔMHCI-iΔB8 CPXV (MOI 5). Cells were incubated at 37°C, 5% CO2. After 1 h at 37°C, 
GolgiPlug (BD Biosciences) was added to each well. Three hours later, cells were stained on ice 
with Fixable Viability Dye eFlour 506 (eBioscience) before staining of cell surfaces for the 
indicated surface markers. Cells were then fixed/permeabilized and stained for IFN-γ. 
Background levels were determined using cells from uninfected mice, which usually ranged 
between 0.01-0.05%, and were subtracted from the values presented. For intracellular staining of 
GzmB and tetramer staining, cells were stained ex vivo without stimulation and without 
incubation with GolgiPlug. H-2Kb-TSYKFESV tetramers were produced in the 
Immunomonitoring Laboratory within the Center for Human Immunology and Immunotherapy 
Programs (Washington University). The following monoclonal antibodies were obtained from 
ThermoFisher, BD Biosciences or eBioscience: CD3 (145-2C11), CD8α (53-6.7), CD8β 
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(eBioH35-17.2), CD4 (RM4-5), CD44 (IM7), CD62L (MEL-14), GzmB (GB12), KLRG1 (2F1), 
CD127 (A7R34) and IFN-γ (XMG1.2).  
 
Statistics 
The data are shown as mean ± SEM and were analysed with an unpaired Student t test or one-
way ANOVA followed by Tukey posttest comparison using Prism GraphPad software, asterisks 
indicate statistical significance and the p values are denoted as *p<0.05, **p<0.01, ***p<0.001.  
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Figures and Tables 
Fig 2.1 Secretion of the immunodominant antigen is not required for immunodominance 
(A) Schematic representation of the B8-mCherry fusion proteins; the location of the signal 
peptide, GGSGGS linker, TMD, and mCherry are depicted. (B) B8TMmC is not secreted. HeLa 
cells were infected at an MOI of 5 with B8TMmC or B8MC. Cells and supernatant were 
harvested at 4 hpi for subcellular fractionation and mCherry and EGFR expression was 
determined by western blot; equal loading and transfer of samples was confirmed with ponceau S 
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red (P-Red) staining. CE = cytoplasmic extract; ME = membrane extract; SN = supernatant. Data 
are representative of two independent experiments. (C, D) Comparable CTL priming by 
B8TMmC and B8mC. CD8+ T cell responses in the spleen of B6 (n = 5) i.n. infected with 5 x 
103 pfu (C) and 1.5 x 104 pfu (D) B8TMmC or B8mC were determined by ex vivo restimulation 
with CPXV peptides and ICS at 8 dpi. Data are representative of two independent experiments. 
(E) Cell-associated antigen is cross-presented more efficiently than soluble antigen. B8-specific 
CD8+ T cell responses in the spleen of B6 (n = 5) i.n. infected with 1.5 x 105 pfu B8TMmC or 
B8mC were determined by tetramer staining at 8, 9, and 10 dpi. Data are representative of two 
independent experiments. (F) CD8+ T cell responses require BATF3+ DCs. B6 and Batf3-/- mice 
(n = 7-10) were i.n. infected with 5 x 103 pfu B8TMmC or B8mC and the B8-specific CD8+ T 
cell responses in the spleen were determined at 6 dpi. n = 3 mock-infected mice. Data are the 
combined results of three independent experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
41 
 
Fig 2.2 Cross-priming induces CTL responses during CPXV infection. (A) BATF3+ DCs 
cross-prime CPXV-specific CTL precursors. B6 or Batf3-/- mice (n = 6) were infected i.p. with 1 
x 105 pfu WT CPXV, ΔMHCIi, or VACV-WR, and CD8+ T cell responses were measured by ex 
vivo restimulation with infected DC2.4 cells and ICS at 8 dpi. The data are the combined results 
of three independent experiments. (B) Induction of VACV-specific CTLs is not dependent 
BATF3+ DCs. B6 or Batf3-/- mice (n = 6-7) were infected i.p. with 1 x 105 pfu VACV-WR and 
CD8+ T cell responses in the spleen were measured at 6 dpi. The data are the combined results of 
two independent experiments. 
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Fig 2.3 Conventional cross-priming, but not cross-dressing, is the main mechanism driving 
CTL responses during CPXV infection. (A) Schematic of BMC cross-dressing experiment. B) 
CTLs are not activated by cross-dressed APCs. Batf3-/- -F1 mice (n = 5-6) were depleted of NK 
cells, lethally irradiated 2 days after NK cell depletion, and reconstituted with 1 x 107 T cell 
depleted BM cells from B6 or BALB/c mice. 8 weeks later, chimeric mice were infected i.n. with 
5 x 103 pfu WT CPXV and CD8+ T cell responses in the lungs were determined by ICS at 8 dpi. 
(C) Memory CTLs are not activated by cross-dressed APCs. Chimeric mice (n = 3-5) previously 
infected for 25 days were challenged with 5 x 104 pfu WT CPXV and CD8+ T cell responses in 
the lungs were determined by ICS at 8 days after challenge. The data are the combined results of 
three independent experiments. 
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Fig 2.4 Cryptic subdominant epitopes can compensate for the loss of the CPXV 
immunodominant epitope-specific CTL response, revealing immunodomination. CTL 
immunodomination occurs during primary responses against CPXV. (A and B) B6 mice (n = 11-
13) were infected i.n with 5 x 103 pfu of WT, ΔB819-26, ΔMHCIi, or ΔMHCIiΔB819-26 and were 
sacrificed at 8dpi. CD8+ T cells in the lungs were restimulated with B819-26 peptide or DC2.4 
cells infected with ΔMHCIi or ΔMHCIiΔB819-26. The legend to B indicates the viruses used for 
infections and the X-axis indicates the stimuli used for ex vivo restimulation and ICS. Data are 
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the combined results of five independent experiments. (C) WT and mutant viral strains replicate 
to similar titers. Viral titers in the lungs of infected B6 mice were determined at 8 dpi by plaque 
assay. (D) Comparable CTL responses against all viral strains tested. B6 mice (n = 6) were 
infected by i.p. and splenic CD8+ T cells were restimulated with peptides or (E) with DC2.4 cells 
infected with ΔMHCIi or ΔMHCIiΔB819-26. Data are the combined results of four independent 
experiments.  
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Fig 2.5 CPXV subdominant epitope-specific memory CTLs immunodominate responses by 
naïve CD8+ T cells. (A) Schematic of i.n. prime/boost experiment. (B and C) 
Immunodomination of naïve CD8+ T cells. B6 mice (n = 5-6) were primed i.n. with 5 x 103 pfu, 
i.n. boosted at 25 dpi with 5 x 103 pfu (B) or 5 x 104 pfu (C), and sacrificed 8 days after boosting. 
CD8+ T cell responses in the lungs (top) and spleens (bottom) were determined by ICS. Data are 
the combined results from two independent experiments. (D) Generation of memory CD8+ T 
cells. i.n. primed mice were sacrificed at 25 dpi and memory CD8+ T cells were measured in the 
spleen by ICS. (E) Antibody-independent memory CTL immunodomination. µmT mice were 
primed by s.s. with 1 x 105 and i.n. boosted with 1 x 105 pfu at 25 dpi. CD8+ T cell responses in 
the spleens were determined 7 days after boost. Data are the combined results from two 
independent experiments. (F) Memory CTLs cross-compete for peptide-MHCI complexes on 
APCs. Peptide-pulsed DCs were adoptively transferred by tail vein injection into ΔB819-26-
primed B6 mice (n = 4) and CD8+ T cell responses in the spleen were evaluated by ICS 6 days 
after transfer. (G) Naïve CD8+ T cells do not cross-compete for peptide-MHCI complexes on 
APCs. Peptide-pulsed BMDCs were transferred into naïve B6 mice and CD8+ T cell responses 
were evaluated by ICS as in the experimental setup of F. Data are representative of two 
independent experiments.  
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Fig 2.6 CPXV subdominant epitopes gain dominance when the relative abundance of 
subdominant antigens is increased during primary responses. (A) Schematic of co-infection 
experiment. Splenocytes were harvested from B6 mice and infected at an MOI of 5 with WT 
CPXV and ΔB819-26 separately or mock-infected. At 1 hpi, infected cells were mixed at different 
ratios and a total of 1 x 105 infected cells were administered into naïve B6 mice (n = 5-6) by tail 
vein injection. (B) A role for antigen levels in CTL immunodomination. Mice were sacrificed at 
7 dpi and splenic CD8+ T cells were restimulated with B8 peptide or (C) with DC2.4 cells 
infected with ΔMHCIi. Data are the combined results from two independent experiments. 
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Fig 2.7 Subdominant epitope-specific CTL responses protect against CPXV infection. (A) 
Schematic of adoptive transfer experiment. B6 mice were primed with ΔB819-26 or MCMV by 
s.c. and i.p. routes, respectively. At 7 dpi, splenic CD8+ T cells were isolated by positive 
selection and adoptively transferred into naive B6 mice (n = 11-13) by tail vein injection. After 
~1 day, mice were infected by i.n. inoculation with ΔB819-26 or ΔMHCIiΔB819-26 and monitored 
for survival (B) and weight loss (C). Data are the combined results from two independent 
experiments.  
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S2.1 Fig. Cross-dressing by hematopoietic cells does not induce CTL responses during 
CPXV infection. (A) Schematic of BMC cross-dressing experiment. 
(B) Hematopoietic cells do not contribute to CTL-priming via cross-dressing of APCs. Lethally 
irradiated Batf3-/- -F1 mice (n = 8) reconstituted with a 1:1 mixture of BALB/c-Thy1.1 and Batf3-
/--F1 bone BM cells were infected i.p. with 1 x 105 pfu WT CPXV and assessed as in the 
experimental setup in Fig 3. n = 4 WT-F1 CPXV-infected mice. The data are the combined 
results of three independent experiments. 
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S2.2 Fig. Mutating the CPXV immunodominant CD8+ T cell epitope anchor residues alters 
peptide binding affinity to MHCI H-2Kb, but does not affect CPXV replication and 
virulence. Peptide binding assays were performed using RMA-S cells. (A) Peptide anchor 
residues are critical for H-2Kb binding. Cell surface staining of H-2Kb after incubation with 
peptide (black) or without peptide (red) are shown; isotype control staining is shown in grey. 
Data are representative of three independent experiments. (B) B8 mutations do not affect viral 
kinetics in vitro. Vero cells were infected at an MOI of 0.01 for multi-step growth curves. Data 
are the combined results of three independent experiments performed in duplicates. (C) B8 
mutations do not affect viral pathogenesis in vivo. B6 mice (n = 5-9) were infected i.n. with 4 x 
104 pfu of the indicated viruses and monitored for survival and weight loss.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
53 
 
S2.3 Fig. Cross-priming of cryptic subdominant epitopes can compensate for the loss of the 
CPXV immunodominant epitope-specific CTL response. 
Peptide anchor residues are critical for inducing B8-specific CTL responses. (A and B) B6 mice 
(n = 10) were infected i.n with 5 x 103 pfu WT, ΔB819-26, ΔMHCIi, or ΔMHCIiΔB819-26 and were 
sacrificed at 8dpi. The B8-specific CTL response was evaluated by tetramer staining. Data are 
the combined results from two independent experiments. (C and D) Comparable CTL responses 
against all viral strains. B6 mice (n = 5) were infected and sacrificed at 8 dpi as in experimental 
setup of A and B. Cell surface expression of CD62L, CD44 and intracellular GzmB was 
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determined for CD8+ T cells in the lungs. Data are representative of three independent 
experiments. (E) BATF3+ DCs cross-prime SDE-specific CTL precursors. B6 or Batf3-/- mice (n 
= 7) were infected i.p. with 1 x 105 pfu ΔB819-26 and CD8+ T cell responses were measured by ex 
vivo restimulation with ΔMHCIiΔB819-26-infected DC2.4 cells and ICS at 8 dpi. Data are the 
combined results from two independent experiments. 
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S2.4 Fig. Viral MHCI inhibition does not affect the generation of memory CD8+ T cells 
(A and B) Generation of memory CD8+ T cells following CPXV infection. B6 mice (n = 7) were 
primed i.n. with 5 x 103 pfu WT or ΔMHCIi and were sacrificed at 25 dpi. Cell surface 
expression of memory T cell markers (CD62L, CD44, KLRG1, and CD127) was determined for 
TET+ CD8 T cells in the spleen. Data are the combined results from two independent 
experiments. 
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S2.5 Fig. CPXV-immunized mice survive lethal challenge in the absence of memory CD8+ T 
cells 
(A) Schematic of immunization and challenge experiment. B6 mice (n= 6-7) were primed i.n. 
with 5 x 103 pfu of CPXV and lethally challenged at 25 dpi. Anti-CD8α or isotype control 
antibodies were administered at the indicated times. (B) Complete depletion of CD8+ T cells. 
The efficiency of antibody-mediated CD8 depletion was determined one day after the first 
administration of antibodies. (C) CPXV immunized mice generate protective antibody responses. 
Challenged mice were monitored for survival and weight loss.  
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S2.1 Table. Primer sequences. 
 
 
S2.2 Table. Synthesized gene fragments. 
 
 
S2.3 Table. Viruses used in this study. 
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Chapter 3:  
Viral MHCI inhibition evades tissue-resident 
memory CD8+ T cell (TRM) responses, but not 
local antigen-driven TRM formation 
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Abstract 
Tissue-resident memory CD8+ T cells (TRM) confer rapid protection and immunity against viral 
infections. Many viruses have evolved mechanisms to inhibit MHCI presentation in order to 
evade cytotoxic CD8+ T cells (CTLs), suggesting that these mechanisms may also apply to TRM-
mediated protection. However, the effects of viral MHCI inhibition on the function and 
generation of TRM is unclear. We show that viral MHCI inhibition dampens immunodominance 
within the lung TRM pool, indicating an effect on the TRM repertoire, but this effect is not elicited 
in the skin. Unexpectedly, local cognate antigen enhances CD8+ TRM development even in the 
occurrence of viral MHCI inhibition and CTL evasion. However, local cognate antigen is not 
required for CD8+ TRM maintenance. We also show that viral MHCI inhibition efficiently evades 
CD8+ TRM effector functions. Our findings suggest that the T cell receptor (TCR) signaling 
threshold for CTL-mediated cytotoxicity and TRM activation may be higher than the threshold for 
antigen-driven differentiation of CTLs to TRM. 
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Introduction 
Cytotoxic CD8+ T cells (CTLs) mediate potent immunity against viral infections and 
respond to foreign antigens presented by major histocompatibility complex I (MHCI) molecules 
59–61. The importance of MHCI antigen presentation is underscored by the fact that viruses have 
evolved strategies to obstruct MHCI presentation. For instance MHCI inhibition by cowpox 
virus (CPXV) evades CTL responses during primary infections, and the absence of the 
endogenous MHCI inhibitors CPXV012 and CPXV203 significantly attenuates CPXV in a CTL-
dependent manner 31,36,52. Moreover, the ability to inhibit MHCI presentation appears to be an 
evolutionarily conserved feature among cytomegaloviruses (CMVs) and other viruses. Viral 
MHCI inhibition evades CTL responses against murine CMV (MCMV) infection in the salivary 
glands (SGs) of naïve hosts and is critical in allowing for rhesus CMV (RhCMV) superinfection 
of hosts harboring memory CD8+ T cells 72,119. However, tissue-resident memory CD8+ T cells 
(TRM) are able to protect against local infection when MCMV is directly introduced into the SGs, 
likely due to an early viral tropism for cells refractory to viral MHCI inhibition 120. Therefore, 
the affects of viral MHCI inhibition on CD8+ TRM responses remain unclear. 
CD8+ TRM typically form in non-lymphoid tissues following viral infection and are a non-
circulating subset of memory T cells, whereas the effector memory T cell (TEM) and central 
memory T cell (TCM) subsets continuously recirculate 121. Because CD8+ TRM primarily develop 
and remain at common sites of pathogen entry, they are considered a front-line defense against 
secondary or recurrent peripheral infections; both CD8+ and CD4+ TRM promote viral control and 
survival against lethal infection, mediate cross-strain protection, and can even provide better 
protection than the circulating TRM counterparts 122–127.  
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The factors driving TRM development have implications for tissue-specific vaccine 
strategies. For example, the ‘prime and pull’ strategy demonstrates that CTLs can be recruited to 
the skin or vagina in an antigen-independent manner and drive TRM formation, resulting in long-
term immunity against local challenge 124,128. Conversely, recruitment or inflammation alone 
does not generate TRM in the lungs unless local cognate antigen is present 129,130, indicating 
tissue-specific requirements for local cognate antigen during TRM differentiation. Depots of 
persisting viral antigens in the lung may also affect the maintenance of memory T cells 131,132. 
However, it is unknown whether persistent antigen presentation occurs in the skin or if MHCI 
complexes are important for the maintenance of endogenous skin CD8+ TRM. In the context of 
viral infections, local cognate antigen recognition promotes the formation of CD8+ TRM in the 
skin, and is required for CD8+ TRM formation in the central nervous system, peripheral nervous 
system, and the lungs 124,133–136.  
These findings on the potential role of local antigen during viral infection raise an 
interesting question: can viral MHCI inhibition affect local antigen recognition and reduce CD8+ 
TRM formation? To investigate this issue, here we compared CD8+ TRM formation and protection 
following local infection with CPXV, which effectively downregulates MHCI and evades CTLs 
in vivo 31,36,52,53, and a CPXV mutant lacking the capacity to inhibit MHCI presentation. 
Surprisingly, viral MHCI inhibition affected CD4+ TRM formation, but not CD8+ TRM formation, 
in the skin. We found that local secondary antigenic stimulation promoted CD8+ TRM formation, 
despite CPXV-mediated MHCI inhibition and CTL evasion. After TRM differentiation, local 
cognate antigen presentation was dispensable for TRM maintenance, but was critical by infected 
cells to induce protective CD8+ TRM responses.    
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Results 
Viral MHCI inhibition affects the formation of CD4+ TRM, but not CD8+ TRM  
CPXV mediates MHCI inhibition, which likely results in lower levels of local antigenic 
stimulation of virus-specific CTLs by infected cells. Because local antigenic stimulation 
enhances CD8+ TRM formation during vaccinia virus (VACV) skin infection 133, we hypothesized 
that CD8+ TRM formation would be diminished in CPXV-infected skin. To test this, we infected 
mice by skin scarification (s.s.) with WT or Δ12Δ203-CPXV and performed kinetic analyses of 
CD8+ T cells that recognize the immunodominant H-2Kb-restricted epitope B819-26. Infection 
with both viruses resulted in robust expansion and recruitment of B819-26-specific CD8+ T cells to 
the skin at 1 week post-infection, which reduced in numbers approximately ~12 fold by 3 weeks 
post-infection (Fig 3.1A). Nonetheless, B819-26-specific CD8+ T cells were still detectable in the 
skin and the spleens of previously infected mice long after clearance of the infection (Fig 3.1, A 
to D); CPXV skin infections are highly localized and are cleared within 1-2 weeks post-infection 
31. Mice infected with WT CPXV had a higher relative abundance of B819-26-specific CD8+ T 
cells in the skin at 7 days post-infection (dpi) in comparison to Δ12Δ203-infected mice (Fig 3.1, 
C and D), but there were no significant differences in absolute numbers in the skin for all 
assessed time points.  
Analysis of B819-26-specific CD8+ T cells during the memory phase showed that they 
were predominantly located in the previously infected skin flank relative to the uninfected 
contralateral flank (Fig 3.1B). These findings are consistent with previous reports 122,133,134. We 
show that these cells expressed high levels of the TRM markers CD103 and CD69 than the B819-
26-specific CD8+ T cells in the spleen (Fig 3.1, E and F), suggesting that CPXV s.s. infection 
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generates authentic CD8+ TRM. To verify tissue-residency of CD103+CD69+CD8+ cells, we 
performed parabiosis between CD45.1+ naïve mice and CD45.2+ mice previously infected with 
CPXV, referred to as naïve and memory mice respectively (Fig 3.1G). Comparison of the 
CD103+CD69+CD8+ TRM in the skin of naïve and memory parabionts revealed the presence of 
these cells in only the memory parabionts, showing that they are unable to circulate and are 
indeed a resident population (Fig 3.1, H and I). Furthermore, B819-26-tetramer+ cells in the 
spleens equilibrated between memory and naïve parabionts, but B819-26-tetramer+ TRM in the skin 
were only present in memory parabionts (Fig 3.1, J to K). Regarding CD4+ TRM, CPXV s.s. 
generated CD103+CD69+CD4+ T cells in the skin in comparable numbers to CD8+ TRM, and 
parabiosis revealed that these cells were bona fide skin-resident CD4+ T cells (Fig S3.1, A to C). 
Interestingly, we found that viral MHCI inhibition significantly reduced the abundance of these 
CD103+CD69+CD4+ T cells in the skin (Fig S3.1, A and B). Taken together, these results reveal 
that viral MHCI inhibition does not affect the overall development of CD8+ TRM, but does impair 
the formation of CD4+ TRM in the skin.  
CD4+ T cell help is critical for the local development of lung CD8+ TRM 137, but is 
dispensable for the formation of CD8+ TRM in the female reproductive tract 138. To test the role of 
CD4+ T cell help in the development of CD8+ TRM in the skin, we depleted CD4+ T cells by 
injecting depleting antibodies 1 day before infection, and 2 and 5 dpi. This approach eliminates 
CD4+ T cells during acute infection, but allows for their recovery by 30 dpi. CD4+ T cell help 
was not required for priming of CD8+ T cells in the presence or absence of viral MHCI inhibition 
(Fig S3.1, D and E). In accordance with our previous findings 31,52, we found that mice infected 
with WT CPXV by s.s. succumbed to infection in the absence of CD4+ T cell help (Fig S3.1F), 
despite the mounting an anti-CPXV CD8+ T cell response (Fig S3.1, E and F). These results 
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underline the capacity of CPXV to efficiently evade CD8+ T cells and suggest that CD4+ T cell 
help is required to control localized CPXV infection. In contrast, all mice infected with Δ12Δ203 
CPXV survived in the absence of CD4+ T cell help (Fig S3.1F), which is also consistent with our 
previous findings that CD8+ T cells alone are sufficient to control CPXV infection only in the 
absence of viral MHCI inhibition 31,52. Given that Δ12Δ203 did not cause mortality, this 
provided a setting to assess the role of CD4+ T cells in skin CD8+ TRM development. As 
expected, depleting CD4+ T cells during the primary response reduced the overall number of 
CD4+ T cells in the skin of mice previously infected with Δ12Δ203, but did not affect the overall 
development of CD4+ TRM cells since the percentage of CD103+CD4+ T cells in the skin was 
similar in isotype-control treated mice (Fig S3.1, G and H). However, it is possible that these 
cells are not tissue-resident and that they may represent a different subset of CD4+ T cells. 
Surprisingly, the formation of CD8+ TRM cells was augmented in the absence of CD4+ T cell help 
(Fig S3.1, G to I), indicating that CD4+ T cell help is not required for the generation of skin 
CD8+ TRM and may even hinder their development.  
 
Viral MHCI inhibition dampens immunodominance within the lung CD8+ TRM population 
We next assessed the effects of CPXV-mediated MHCI inhibition on lung CD8+ TRM 
since the developmental requirements can differ substantially between certain tissue 
microenvironments 135. In order to distinguish circulating memory CD8+ T cells from TRM we 
performed in vivo intravascular (IV) staining 139. This method exclusively labels circulating and 
intravascular lymphocytes (IV+ cells), but not tissue-associated lymphocytes (IV-). Within the 
lung tissue, the overall proportions of IV-CD8+ T cells were equal in mice infected intranasally 
(i.n.) with WT CPXV or Δ12Δ203 at 12 and 30 dpi, suggesting that viral MHCI inhibition also 
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does not affect lung CD8+ TRM formation (Fig 3.2, A and B). However, higher proportions of IV- 
B819-26-specific CD8+ T cells were found in the lungs following Δ12Δ203 infection compared to 
WT CPXV infection (Fig 3.2C). This difference was also reflected in the spleen and blood at 30 
dpi, despite equal proportions of B819-26-specific CD8+ T cells in the spleen and blood at 12 dpi 
(Fig 3.2, D and E). Viral MHCI inhibition also significantly reduced the expression of CD103 on 
IV- B819-26-specific CD8+ T cells at 12 dpi, but not CD69 expression (Fig 3.2, F and G). The 
reduced expression of CD103 did not appear to affect CD8+ TRM development since IV- B819-26-
specific CD8+ T cells in the lungs of WT CPXV- and Δ12Δ203-infected mice expressed 
comparable levels of CD69 and CD103 by 30 dpi (Fig 3.2, F and G). These data indicate that 
viral MHCI inhibition reduces the immunodominance of the B819-26-specific cells within the 
CD8+ TRM pool. 
 
Local cognate antigen enhances CD8+ TRM cell formation, despite effective viral MHCI 
inhibition and CTL evasion 
Thus far, our results suggest that CD8+ TRM development is independent of local antigen 
stimulation during CPXV infection. However, infection with WT CPXV is prolonged in 
comparison to Δ12Δ203 infection 31, and it is therefore possible that during WT CPXV infection 
continuous recruitment of CTLs may compensate for the decreased secondary antigenic 
stimulation on TRM formation. To test if continuous recruitment of CTLs to the skin augments 
CD8+ TRM formation in the presence of viral MHCI inhibition, we utilized the sphingosine 1-
phosphate receptor-1 (S1PR) agonist FTY720, which prevents lymphocyte egress from lymphoid 
tissues. FTY720 treatment early during infection (1, 3, and 5 dpi) significantly reduced the 
presence of circulating CD8+ T cells in the blood and the recruitment of CD8+ T cells to infected 
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skin, but not priming of B819-26-specific CD8+ T cells in the inguinal lymph node (Fig S3.2, A to 
C). We next performed co-infections of mice with WT CPXV and Δ12Δ203 on opposite flanks, 
then blocked recruitment of CTLs starting at 7 days post-infection (dpi) with FTY720 treatment 
(Fig S3.2D). If continuous recruitment of CTLs compensates for reduced secondary antigenic 
stimulation, we expect that FTY720 treatment would reduce the abundance of CD8+ TRM in WT 
CPXV-infected skin relative to Δ12Δ203-infected skin. While FTY720 significantly reduced the 
presence of CD4+ and CD8+ T cells in the blood of co-infected mice, the relative abundance of 
B819-26-specific CD8+ T cells at 9 dpi and CD8+ TRM cells at 40 dpi was not significantly 
different in the WT CPXV and Δ12Δ203 infected skin, with or without FTY720 treatment (Fig 
S3.2, E and F). These results indicate that CD8+ TRM develop without continuous recruitment of 
CTLs. 
Since CD8+ TRM development occurred despite viral MHCI inhibition, we tested if CD8+ 
TRM formation is independent of local antigen by performing co-infections, on opposite flanks, 
with CPXV viruses that express either a WT (WT and Δ12Δ203-CPXV) or a variant of the 
immunodominant B819-26 epitope (B8Y3AF5A and Δ12Δ203B8Y3AF5A) that is not presented 
on MHCI 36 (Fig 3.3A). During the acute phase of infection, B819-26-specific CD8+ T cells had 
modestly higher frequencies of CD69 expression in the skin where B819-26 was expressed in 
comparison to the skin where the B819-26 epitope was absent, whereas CD103 expression was 
unaffected (Fig S3.3, A and B). Nonetheless, a similar percentage and number of B819-26-specific 
CD8+ T cells were recruited to both infected skin flanks in a local antigen-independent manner 
(Fig 3.3B). This was also the case when co-infections were performed with Δ12Δ203 and 
Δ12Δ203B8Y3AF5A. At 35 dpi, however, B819-26-specific CD8+ T cells were significantly 
enriched in the skin where B819-26 was locally expressed as compared to infection where B819-26 
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was locally absent (Fig 3.3C), even in the presence of CPXV-mediated MHCI inhibition. 
Furthermore, the abundance of total CD8+ TRM was equal on both flanks of co-infected mice (Fig 
3.3D), suggesting that TRM formation was only affected for B819-26-specific CD8+ T cells. Taken 
together, these data indicate that local antigen does promote CD8+ TRM formation during CPXV 
infection, regardless of viral MHCI inhibition. 
 
Viral MHCI inhibition decreases CTL effector function, but not recognition of local 
cognate antigen 
We previously demonstrated that CPXV-mediated MHCI inhibition prevents CPXV-
specific CTLs from recognizing infected cells 31,36,53. Consistent with our previous findings, 
CTLs from CPXV-infected mice did not produce IFN-γ when co-cultured with WT CPXV-
infected DC2.4 cells (Fig 3.4A). This effect was dependent on CPXV012 and CPXV203 as 
CTLs co-cultured with Δ12Δ203-infected DC2.4 cells produced significantly higher levels of 
IFN-γ and upregulated expression of Nur77 (Fig 3.4A), a transcription factor that is specifically 
induced upon TCR engagement 140, as compared to WT CPXV-infected cells. However, our 
results suggest that CPXV-specific CTLs can receive antigenic stimulation at the site of infection 
in vivo (Fig 3.3). 
To test if our in vitro findings extend to in vivo infection, we co-infected IFN-γ.Thy1.1 
knockin reporter mice with WT and Δ12Δ203 CPXV on opposite flanks. Similar to our previous 
findings 31, CPXV s.s. resulted in significantly higher frequencies of IFN-γ-producing CD8+ T 
cells in Δ12Δ203-infected skin in comparison to WT CPXV-infected skin (Fig 3.4B). 
Conversely, the frequency of Nur77+CD8+ T cells was not significantly different. We also found 
similar results following co-infection of Nur77 GFP reporter mice (Fig S3.3C). In accordance 
 
 
69 
with our findings that local cognate antigen promotes TRM formation (Fig 3.3C), these findings 
suggest that CTLs recruited to CPXV-infected skin receive local cognate antigen stimulation, 
despite viral MHCI inhibition and efficient CTL evasion by CPXV.  
To identify the cells that could display local cognate antigen, we assessed CPXV tropism 
in the skin of mice infected by CPXV s.s. There was significant recruitment of leukocytes in the 
skin at 6 dpi (Fig 3.4C). The majority of infected cells were MHCII/CD45 double positive and 
comprised of mainly CD11b+ dendritic cells (DCs) and monocyte-derived DCs (moDCs) (Fig 
3.4, D and E). Moreover, CPXV+ and MHCII+ cells were found in close proximity to CD8+ cells 
(Fig 3.4F), suggesting that CTLs may likely engage infected CD11b+ DCs or moDCs at the site 
of infection; though viral MHCI inhibition should prevent virus-specific T cell stimulation. 
Strikingly, CD103+ DCs were largely uninfected (Fig 3.4E), but were also found in close 
proximity to CD8+ cells at the site of infection (Fig 3.4F), suggesting CTLs in the skin may be 
engaging cross-presenting cells that are also involved in priming of naïve CPXV-specific CTL 
precursors 31,36 
 
CD8+ TRM in the skin persist in the absence of cognate antigen stimulation 
Having established the importance of local cognate antigen in CD8+ TRM formation 
against CPXV, we questioned whether local cognate antigen plays a role after CD8+ TRM 
populations are established. To address this, we generated B2mfl/flRS26-Cre-ERT2 mice in which 
tamoxifen treatment ablates MHCI expression. B2mfl/flRS26-Cre-ERT2 mice infected by s.s. were 
treated with tamoxifen at 49 dpi and CD8+ TRM were analyzed in the skin approximately one 
month after treatment (Fig 3.5A). Tamoxifen treatment eliminated expression of MHCI on 
CD45+ cells from the skin and spleen of B2mfl/flRS26-Cre-ERT2 mice (Fig 3.5B), but not from 
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tamoxifen treated B2mfl/fl littermate controls. We detected B819-26-specific TRM at comparable 
levels in the skin of tamoxifen-treated B2mfl/flRS26-Cre-ERT2 and B2mfl/fl mice (Fig 3.5C), 
indicating that persistent antigen presentation is not required for CD8+ TRM maintenance. This 
was also observed for total CD8+ TRM in the skin (Fig 3.5D). Furthermore, we assessed TCR 
engagement on CD8+ TRM using the Nur77 GFP reporter mice and found that CD8+ TRM are 
Nur77-negative (Fig 3.5E). Therefore, CD8+ TRM do not receive cognate antigen stimulation in 
the skin and are maintained in an antigen-independent manner.  
 
Viral MHCI inhibition evades local CD8+ TRM responses 
Since viral MHCI inhibition evades CTL responses during primary CPXV infection, we 
next sought to investigate the effects of viral MHCI inhibition on CD8+ TRM effector function in 
the absence of other anti-CPXV immune responses. To do so we generated a recombinant 
influenza virus that expresses the CPXV B819-26 epitope (Flu-B8) and infected mice by the i.n 
route. This resulted in the formation of B819-26 -specific TRM in the lungs of infected mice at 30 
dpi (Fig S3.4). We next challenged the mice with CPXV at 30 dpi (Fig 3.6A). To prevent 
circulating memory CD8+ T cells from contributing to viral control upon CPXV challenge, we 
treated Flu-B8-infected mice with FTY720 throughout the course of the CPXV challenge. Viral 
titers in the lungs of mice challenged with Δ12Δ203 were significantly lower than in mice 
challenged with WT CPXV (Fig 3.6B), demonstrating that viral MHCI inhibition reduces 
protective CD8+ TRM responses in the lungs. CD8+ TRM-mediated protection was antigen-
dependent since challenge with B8 deficient viruses resulted in titers comparable to challenge 
with WT CPXV. 
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To test if these findings also hold true during CPXV skin infection, we used µMT mice, 
which lack mature B cells, in order to avoid humoral responses against CPXV challenge. µMT 
mice previously infected by s.s. with Δ12Δ203 harbored few B819-26 -specific CD8+ TRM in the 
skin (Fig S3.5), which is consistent with the findings that infection of µMT mice generates 
significantly lower numbers of memory CD8+ T cells in comparison to infection of WT C57BL/6 
mice 141,142. We next tested whether depleting CD4+ T cells during acute infection of µMT mice 
would increase CD8+ TRM formation. Similar to what we observed in WT C57BL/6 mice (Fig 
S3.1, G to I), depleting CD4+ T cells significantly increased CD8+ TRM formation in the skin of 
µMT mice infected by s.s., but not i.n. infection (Fig S3.5). In contrast, depleting CD4+ T cells 
did not significantly increase the number of B819-26 -specific CD8+ T cells in the spleen of µMT 
mice previously infected by s.s. at 30 dpi.  
Based on these findings, we induced CD8+ TRM formation in CD4+ T cell-depleted µMT 
mice by s.s. with Δ12Δ203 and subsequently challenged the skin with WT CPXV and Δ12Δ203 
at 30dpi (Fig 3.6C). Viral titers in the skin of naïve mice were not significantly different in WT 
CPXV and Δ12Δ203-infected lesions 4 days after challenge (Fig 3.6D). Similarly, viral titers 
were not significantly different in previously infected µMT mice lacking skin CD8+ TRM (i.n. 
infected). Conversely, viral titers and scab formation in the Δ12Δ203 lesions of µMT mice 
harboring skin CD8+ TRM (s.s. infected) were significantly reduced (Fig 3.6D). WT CPXV titers 
were also reduced in mice immunized by s.s., although the difference was not statistically 
significant. It is possible that CD8+ TRM activation by Δ12Δ203-infected cells provoked an 
antiviral state in surrounding areas, as previously demonstrated for skin CD8+ TRM 143, and 
thereby protected against WT CPXV infection at adjacent sites. These data indicate that CD8+ 
TRM are protective against CPXV, but more so in the absence of viral MHCI inhibition. 
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Interestingly, similar results were obtained in µMT mice treated with isotype control antibodies 
(Fig 3.6E).  
 
Discussion 
In this study, we assessed the effects of viral MHCI inhibition on the generation and 
function of TRM. While viral MHCI inhibition prevents CTL-mediated viral clearance, curiously 
it does not appear to obstruct local antigenic stimulation of CTLs and subsequent CD8+ TRM 
formation. Consistent with what was previously reported for VACV skin infection 133,134, local 
antigenic stimulation promoted CD8+ TRM formation in CPXV-infected skin. Our findings 
suggest that local antigenic stimulation of CTLs may promote CD8+ TRM development without 
eliciting T cell-mediated cytotoxicity or cytokine production directed against infected cells.  
Our findings also raise the possibility that TRM precursors receive local antigenic 
stimulation from cross-presenting cells in situ 144,145. This possibility would explain why local 
antigen stimulation enhances TRM formation that is not significantly affected by the presence of 
viral MHCI inhibition. Since cross-presentation by BATF3+ DCs imprints TRM precursors in the 
lymph nodes 146 and is required for CPXV-specific T cell priming 31,36, these cells are candidates 
for being involved in local cross-presentation; further investigation will be needed to determine 
their relative contribution to in situ cross-presentation on TRM development. Intriguingly, these 
data also raise the possibility that local cross-presentation may be involved in the activation of 
skin CD8+ TRM. 
Local antigen presentation by APCs is critical for the activation of CD8+ TRM in the 
female genital tract and CNS 136,147, but whether direct contact with infected target cells is 
 
 
73 
required for CD8+ TRM functions is uncertain. For instance, in situ peptide stimulation of CD8+ 
TRM is sufficient to induce a tissue-wide antiviral state and protects against antigenically distinct 
viruses 143,148. Therefore, CD8+ TRM activation and protection can ensue independently of direct 
cell-cell contact with infected target cells. Conversely, we found that CD8+ TRM protection 
during viral infection is abrogated by viral MHCI inhibition, suggesting that TCR/peptide-MHCI 
(pMHCI) stimulation via engagement of infected target cells is needed for optimal CD8+ TRM 
functions. Based on the in vivo effect of viral MHCI inhibition, we postulate that the level of 
TCR stimulation needed to trigger CD8+ TRM and CTL effector functions is higher than the level 
needed to promote local antigen-dependent TRM formation.  
 Additionally, TRM development and formation in the lungs of CPXV-infected mice 
remained largely unaffected by viral MHCI inhibition, but viral MHCI inhibition dampened 
immunodominance within the lung TRM pool. Immunodominance is not affected by CPXV012 
and CPXV203 during primary CPXV infection 31,36, but the breadth and the levels of viral 
epitopes presented in the context of viral MHCI inhibition can differ from the epitopes presented 
in the absence of viral MHCI inhibition 57,85. As a consequence, increased antigen presentation 
and antigen abundance during respiratory infection with Δ12Δ203 potentially promotes CTL 
cross-competition for pMHCI complexes, which can affect the TRM repertoire 134,135. These 
findings were not found following CPXV skin infection, suggesting that differences in the 
microenvironment also contribute to the effects on TRM immunodominance. Moreover, 
respiratory viral infections results in persistent antigen presentation 131,149,150, and can contribute 
to the locality of memory T cells 151. Persistent antigen presentation was therefore an appealing 
explanation for the long-term maintenance of TRM in peripheral tissues.  
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Here we used inducible deletion of B2m to test if persistent stimulation is required for 
maintaining TRM. We found that deletion of B2m after TRM formation did not affect the number 
of TRM cells, suggesting that local cognate antigen, or even low-level stimulation from cross-
reactive pMHCI complexes is not required for TRM maintenance. However, since our studies 
focused on the CD45+ compartment, it is possible that low-level expression of MHCI on non-
hematopoietic cells could contribute to TRM maintenance. Nonetheless, our results add to 
previous reports 124,128,152–154 by suggesting that TRM maintenance is also apparently independent 
of cross-reactive pMHCI complexes.  
Ultimately, our findings shed light on the maintenance, generation, and activation of TRM, 
and highlight the effects of viral MHCI inhibition on local CD8+ TRM responses, which should be 
seriously considered in regards to vaccine design against viruses that target the MHCI pathway.  
 
Materials and methods 
Mice, cell lines, and viruses 
C57BL/6 mice were purchased from the National Cancer Institute. Transgenic and knockout 
mice were purchased from the Jackson Laboratory, with the exception of B2mfl/fl and IFNγ KI 
Thy1.1 mice. IFNγ KI Thy1.1 mice were kindly provided by Dr. Casey Weaver, University of 
Alabama School of Medicine. B2mfl/fl mice were generated as described by Bern et al., 2018 
(submitted). DC2.4 cells were cultured in RPMI supplemented with 10% FBS (Mediatech), 100 
U/ml Penicillin, 100 g/ml streptomycin, 1mM sodium pyruvate, L-glutamine, and non-essential 
amino acids (Gibco). Madin–Darby Canine Kidney (MDCK) cells were maintained in MEM 
with 5% FBS, MEM-vitamins (Gibco), L-glutamine, 100 U/ml Penicillin, and 100 g/ml 
streptomycin. Human embryonic kidney cells (293T) were maintained in Opti-MEM (Life 
 
 
75 
Technologies) with 10% FBS, L-glutamine, 100 U/ml Penicillin, and 100 g/ml streptomycin. 
DC2.4 cells were gifted from Dr. Kenneth Rock, University of Massachusetts Medical School. 
MDCK and 293T cells were a kind gift from Dr. Richard Webby at St. Jude Children’s 
Research Hospital. 
For the generation of IAV-B819-26 (Flu-B8), the CPXV B819-26 epitope was inserted 
into the stalk region of neuraminidase (NA), in-frame, between nucleotides 148 and 170 using 
inverse PCR (Phusion-HF, ThermoFisher) and the restriction enzyme AarI (ThermoFisher) to 
ligate the mutant plasmid. Co-cultures of 293T and MDCK cells were transfected with eight 
bidirectional pHW2000 plasmids containing cDNA for A/Puerto Rico/08/1934 (H1N1) (1  µg 
per plasmid) with polyethylenimine (8  µg total). Rescue of the reverse genetic virus was 
performed as previously described 155. BAC-derived CPXV viruses were generated as 
previously described 36.  
 
Mouse infection and parabiosis surgery 
Mice 8-10 weeks of age were sex- and age-matched for each experiment. i.n. and s.s. infections 
were performed as previously described 31. In brief, mice were anesthetized and 30 µl of virus 
inoculum diluted in PBS was administered i.n. For s.s., fur from the flank of mice was depilated 
using Nair™. The following day, mice were anesthetized and the flanks were infected by s.s. at 
three adjacent sites, 1 x 105 pfu/site. Parabiosis surgery was performed as previously described 
156,157. Parabiosed mice were rested for two weeks before sacrificing and harvesting tissues.  
 
Immunofluorescence. 
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2 x 3 cm2 piece of skin was harvested from infected mice and were prepared as previously 
described 158. Sections were blocked using 10% goat serum in PBS for 1h before incubating with 
primary antibodies for 1h. Cells were then washed with 0.5% triton in PBS, incubated with 
Streptavidin-AF555 (ThermoFisher), washed with 0.5% triton in PBS, and mounted with DAPI 
(Vectashield). Stained sections were analysed with laser scanning confocal microscope LSM880 
(Zeiss). Primary antibodies were obtained from BD Pharmingen and include CD103-Biotin 
(M290), IA/IE-AF647 (M5/114.15.2), and CD8α-AF488 (53-6.7). 
 
In vivo antibody, FTY720, and tamoxifen treatment. 
To induce TCR ligation in vivo, 50 µg of anti-CD3e monoclonal antibody (145-2C11; 
ThermoFisher) was administered into mice by i.v. injection 16 hours prior to harvesting tissues. 
FTY720 (Cayman Chemical) was administered by i.p. injection (10 mg/kg) in aqueous solution. 
To deplete CD4+ T cells, 200 µg anti-CD4 (GK1.5) or isotype control (anti-rat IgG2b; Bio X 
Cell) were injected i.p. To deplete NK cells, 100 µg anti-NK1.1 (PK136) was injected i.p. 
weekly. For intravascular staining, fluorochrome-conjugated anti-CD45.2 (104; BioLegend) was 
administered by i.v. injection. Three minutes after injection, mice were sacrificed and tissues 
were harvested. Mice were treated topically with 1 mg 4-hydroxytamoxifen (Sigma-Aldrich) 
dissolved in ethanol and were fed with tamoxifen diet (Envigo) during the indicated times 
shown. 
 
Flow cytometry, intracellular cytokine staining, and antibodies 
Single-cell suspensions from the spleens, lymph nodes, lungs, and ~2 x 3 cm2 piece of skin were 
prepared at the indicated days post-infection as previously described 31,123. Skin and lung tissues 
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were minced and incubated in with Hanks balanced salt solution (HBSS) containing 1 mg/mL 
collagenase A (Roche) and 22.4 g/mL Dnase I (Roch) at 37° C for 30 minutes. Samples were 
then filtered through a 70 µm mesh strainer prior to staining. Samples for flow cytometric 
analyses were stained on ice with Fixable Viability Dye eFlour 506 (eBioscience) before 
tetramer and cell surface staining. For tetramer staining, cells were incubated with H-2Kb-
TSYFESV tetramers for 45 minutes at room temperature prior to cell surface staining of the 
indicated surface markers. Tetramers were produced in the Immunomonitoring Laboratory 
within the Center for Human Immunology and Immunotherapy Programs (Washington 
University). Ex vivo restimulation and intracellular cytokine staining for IFN-γ was performed as 
previously described 36. For staining of Nur77, the Foxp3/Transcription Factor Staining Buffer 
Set was used according to the manufacturer’s protocol (eBioscience). The following antibodies 
were purchased from Abcam, BD Biosciences, eBioscience, BioLegend, or ThermoFisher: CD3 
(145-2C11), NK1.1 (PK136), CD19 (eBio1D3), CD64 (X54-5/7.1), CD8α (53-6.7), CD4 (RM4-
5), VACV (Ab19970), CD4 (RM4-4), CD44 (IM7), CD103 (2E7), CD69 (H1.2F3), H-2Kb (AF-
88.5), CD11c (N418), CD45.1 (A20), CD45.2 (104), CD24 (M1/69), IA/IE (M5/114.15.2), 
SIRPα (P84), CD11b (M1/70), Ly6C (HK1.4), Nur77 (12.14).  
 
Statistic analysis 
The data were analysed with an unpaired Student t test or one-way ANOVA followed by Tukey 
posttest comparison using Prism GraphPad software. Asterisks indicate statistical significance 
and p values are denoted as *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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Fig 3.1 Viral MHCI inhibition does not affect the overall development of CD8+ TRM. 
C57BL/6 mice were infected by s.s. with WT CPXV or Δ12Δ203 (A to F). (A) The absolute 
number of B819-26-tetramer+ cells in the skin (S) and spleen (SP) of infected mice over time. n = 
4 mice per time point. Representative of three independent experiments. (B) The absolute 
number of B819-26-tetramer+ cells in previously infected skin flank and the contralateral 
uninfected skin flank at 49 dpi. (C) Representative flow plots of B819-26-tetramer+ cells in the 
skin at the indicated time points. (D) Percentage (top) and absolute number (bottom) of B819-26-
tetramer+ cells in the skin on 7 dpi and 35 dpi. (E) Representative flow plots of CD103 and 
CD69 expression on B819-26-tetramer+ cells are shown for the indicated time points. (F) 
Percentage of CD103 (Left) and CD69 (Right) expression on B819-26-tetramer+ cells are shown 
for the indicated time points. (G) Schematic of parabiosis experiment. (H) Representative flow 
plots of CD103+CD69+ skin CD8+ T cells in parabiosed mice. (I) Percentage and absolute 
numbers of CD103+CD69+ skin CD8+ T cells in parabiosed mice. (J) The absolute number of 
B819-26-tetramer+ TRM in the skin of parabiosed mice. (K) Percentage of B819-26-tetramer+ cells in 
the spleen of parabiosed mice. Representative of three independent experiments (for panel A to 
F). Data were pooled from two independent experiments (for panel H to K). Symbols represent 
individual mice. Error bars represent means ± SEM. 
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Fig 3.2 Viral MHCI inhibition affects immunodominance within the lung CD8+ TRM 
population.  
C57BL/6 mice were infected i.n. with WT CPXV or Δ12Δ203. Intravascular staining with an 
anti-CD45 antibody was performed before euthanizing mice at 12 and 30 dpi. (A) Representative 
flow plots of CD45 expression on CD8+ cells in the lungs (Lu). Data are representative of two 
independent experiments. (B) Percentage of IV-CD8+ cells in the lungs at 12 (top row) and 30 
(bottom) dpi. Data are pooled from two independent experiments. Symbols represent individual 
mice. Error bars represent means ± SEM. (C) Percentage of IV-CD8+B819-26-tetramer+ cells in 
the lungs at 12 (top row) and 30 (bottom) dpi. (D and E) Percentage of IV-CD8+B819-26-tetramer+ 
cells in the blood (Bl) and spleen (SP) are shown at 12 and 30 dpi. Data are pooled from two 
independent experiments. Symbols represent individual mice. Error bars represent means ± 
SEM. (F) Representative flow plots of CD69 or CD103 expression on IV+/IV- B819-26-tetramer+ 
cells at 12 and 30 dpi. (G) Percentage of CD69 and CD103 expression on IV-/IV- B819-26-
tetramer+ cells at 12 (top) and 30 (bottom) dpi. Data are pooled from two independent 
experiments. Symbols represent individual mice. Error bars represent means ± SEM. 
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Fig 3.3 Local cognate antigen enhances CD8+ TRM formation, even in the context of viral 
MHCI inhibition and CTL evasion.  
(A) C57BL/6 mice were co-infected by s.s. with B819-26 sufficient CPXV (WT or Δ12Δ203) and 
B819-26 deficient (B8Y3AF5A or Δ12Δ203B8Y3AF5A). (B) Representative flow plots of B819-26-
tetramer+ cells in the skin at 7 dpi are shown above the percentage and absolute number of B819-
26-tetramer+ cells. (C) Representative flow plots of B819-26-tetramer+ cells in the skin at 35 dpi are 
shown above the percentage and absolute number of B819-26-tetramer+ cells. (D) Representative 
flow plots CD69 and CD103 expression on CD8+ cells in the skin at 35 dpi are shown above the 
percentage and absolute number of CD69+CD103+ CD8+ cells. Data are pooled from two 
independent experiments. Symbols represent individual mice. Error bars represent means ± 
SEM. 
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Fig 3.4 Viral MHCI inhibition evades CTL responses, but does not affect TCR engagement 
with cognate antigen/MHC complexes on infected target cells in vivo.  
C57BL/6 mice or Thy1.1 KI IFN-γ reporter mice were co-infected with WT CPXV and 
Δ12Δ203. The spleens of infected C57BL/6 mice and skin of infected Thy1.1 KI IFN-γ reporter 
mice were harvested for ex vivo restimulation and direct ex vivo analyses respectively on 7 dpi. 
(A) Percentage of endogenous IFN-γ and Nur77 expression on CD8+ cells stimulated with WT 
CPXV or Δ12Δ203-infected DC2.4 cells. Data are pooled from two independent experiments. 
(B) Percentage of IFN-γ (Thy1.1) and endogenous Nur77 expression on CD8+ cells from WT 
CPXV or Δ12Δ203-infected skin. Data are pooled from three independent experiments. Symbols 
represent individual mice. Error bars represent means ± SEM. (C to F) C57BL/6 mice were 
infected by s.s. with WT CPXV and sacrificed on 6 dpi. (C) Absolute number of leukocytes 
recruited to WT CPXV-infected skin. Cells from the skin were gated on CD45+ and defined as 
follows: NK (CD3-CD19-NK1.1+), CD19 (CD3-CD19+; CD4, CD19-CD3+CD4+), CD8 (CD19-
CD3+CD8+), CD103+ DC (MHCII+CD11c+CD24+SIRPα-CD103+), CD11b+ DC 
(MHCII+CD24+CD64-CD11b+), Ly6C+ Mo/Mϕ (MHCII-CD64+CD11b+Ly6C+), Ly6C- Mo/Mϕ 
(MHCII-CD64+CD11b+Ly6C-), moDC (MHCII+CD11b+CD64+CD24+), granulocytes (MHCII-
CD24+CD11b+) (D) Percentage of CPXV+ cells, as determined by staining with α-VACV 
antibodies and flow cytometric analysis. (E) Percentage of CPXV+ cells within the CD45+ 
population. Data are representative of two independent experiments. Symbols represent 
individual mice. Error bars represent means ± SEM. (F) Immunofluorescence staining of CD8+, 
CD103+, CPXV+ and MHCII+ cells in the skin at 6 dpi. Scale bars, 50 µm. 
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Fig 3.5 CD8+ TRM are maintained in the absence of cognate antigen stimulation. 
B2mfl/flRS26-Cre-ERTT2 mice and B2mfl/fl litter mate controls were infected by s.s. with WT 
CPXV. On 49 dpi, mice were started on a tamoxifen chow diet and treated topically with 4HT 
daily for 5 days. Additionally, mice were treated with α-NK1.1 (100 µg/mouse) once weekly 
starting on 49 dpi to deplete NK cells. (A to D) Mice were euthanized at 76 dpi and CD8+ T cells 
were analyzed in the skin (S) and spleen (SP). (B) Representative flow plots of H-2Kb expression 
on CD45+ cells from the skin and spleen on 76 dpi. (C) Percentage of B819-26-tetramer+ and 
CD69+CD103+ cells in the skin and spleen at 76 dpi. (D) Percentage of total CD8+ and 
CD69+CD103+ cells in the skin at 76 dpi. Data are pooled from two independent experiments. 
Symbols represent individual mice. Error bars represent means ± SEM. (E) Nur77GFP reporter 
mice and nontransgenic (NTg) littermate controls were infected by s.s. with WT CPXV and 
euthanized at 30 dpi. CD8+ T cells were analyzed in the skin and spleen. As a positive control, 
B8 peptide was administered intradermally (i.d.) and an α-CD3 antibody was administered 
intravenously (i.v.) into Nur77GFP mice previously infected for 30 days. Representative flow 
plots of Nur77 (GFP) and CD69 expression on skin and splenic CD8+ T cells is shown. Data are 
representative of three independent experiments; total n = 3 positive control mice, total n = 5 
Nur77GFP mice, and total n = 6 Ntg mice.   
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Fig 3.6 Viral MHCI inhibition evades protective CD8+ TRM responses.  
(A) Schematic of heterologous prime/challenge experiment. (B) Viral titers in the lungs of Flu-
B8-immunized mice challenged with CPXV. Data are pooled from two independent 
experiments. (C) Schematic of µmT mice skin challenge experiment. (D) Image of infected µmT 
flanks (left) and viral titers from skin lesions 4 days after s.s. challenge of α-CD4 treated naïve 
control and CPXV-immunized µmT mice. (E) Viral titers from skin lesions 4 days after s.s. 
challenge of isotype control treated CPXV-immunized µmT mice. Data are pooled from two or 
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three independent experiments. Symbols represent individual mice. Error bars represent means ± 
SEM. 
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Fig S3.1 Viral MHCI inhibition affects the formation of CD4+ TRM.  
C57BL/6 mice were infected by s.s. with WT CPXV or Δ12Δ203. (A) Representative flow plots 
of CD103 and CD69 expression on CD4+ and CD8+ cells in the skin at 35 dpi. (B) Percentage of 
CD69+CD103+ T cells in the skin at 35 dpi. Representative of three independent experiments. 
Symbols represent individual mice. Error bars represent means ± SEM.  (C) The absolute 
number of CD4+ TRM in the skin of parabiosed mice. Parabiosis was performed as outlined in 
Figure 1G. (D to I) Mice infected by s.s. with WT CPXV or Δ12Δ203 were treated with α-CD4 
or isotype control antibodies on day -1, 2, and 5 post-infection. (D) Representative flow plots of 
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peripheral blood T cells and B819-26-tetramer+ cells at 7 dpi. (E) Percentage of B819-26-tetramer+ 
cells from peripheral blood at 7 dpi. (F) Percent survival. n = 10 mice per group. Data are pooled 
from two independent experiments. (G) Absolute number of CD4+ and CD8+ T cells in the skin 
at 30 dpi. (H) Percentage of CD103 expression on T cells at 30 dpi. (I) Percentage (left) and 
absolute numbers (right) of B819-26-tetramer+ cells in the skin at 30 dpi. Data are pooled from two 
independent experiments. Symbols represent individual mice. Error bars represent means ± 
SEM. 
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Fig S3.2 CD8+ TRM develop without continuous recruitment of CTLs during acute CPXV 
infection.  
C57BL/6 mice were co-infected with WT CPXV and Δ12Δ203 and FTY720 was subsequently 
administered by intraperitoneal (i.p.) injection on 1, 3, and 5 dpi (A to C). CD8+ T cells were 
analyzed in the skin (S), blood (Bl), and inguinal lymph node (iLN) at 6 dpi. (A) Representative 
flow plots. n = 9-15 mice per group. Data are representative of two independent experiments. (B) 
Percentage of CD8+ cells. Data are pooled from two independent experiments. Error bars 
represent means ± SEM. (C) Percentage of B819-26-tetramer+ cells in the iLN at 6 dpi. Data are 
pooled from two independent experiments. Error bars represent means ± SEM. (D) Schematic of 
co-infection experiment. T cells from peripheral blood (E) and B819-26-tetramer+ cells in the skin 
(F) of mice infected as shown in (D) were analyzed at the indicated time points. Data are pooled 
from two independent experiments. Symbols represent individual mice. Error bars represent 
means ± SEM. 
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Fig S3.3 Local cognate antigen recognition upregulates CD69 and Nur77 expression by 
CTLs.  
C57BL/6 mice were co-infected by s.s. with B819-26 sufficient CPXV (WT or Δ12Δ203) and 
B819-26 deficient (B8Y3AF5A or Δ12Δ203B8Y3AF5A) on opposite flanks. (A) Percentage of 
B819-26-tetramer+ cells expressing CD69 at 7 dpi. (B) Percentage of B819-26-tetramer+ cells 
expressing CD103 at 7 dpi.  Data are representative of two independent experiments. Symbols 
represent individual mice. (C) Nur77GFP mice were co-infected as outlined in Fig. 3A. Nur77 
(GFP) expression by CD8+ T cells from WT CPXV or Δ12Δ203-infected skin was analyzed at 7 
dpi. Data are pooled from two independent experiments. Symbols represent individual mice. 
Error bars represent means ± SEM. 
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Fig S3.4 Flu-B8 respiratory infection generates B819-26 -specific CD8+ TRM in the lungs. 
C57BL/6 mice were i.n. infected with recombinant Flu virus expressing the CPXV B819-26 
epitope. Intravascular staining with an anti-CD45 antibody was performed before euthanizing 
mice at 30 dpi. (A) Percent of B819-26-tetramer+ and NP366-374-tetramer+ IV-cells in the lungs of 
Flu-B8-infected mice. Data are pooled from two independent experiments. Symbols represent 
individual mice. Error bars represent means ± SEM. (B) Representative flow plots of CD103 
expression on tetramer+IV- cells at 30 dpi. (C) Percentage of CD103+TET+IV- cells. Data are 
pooled from two independent experiments. Symbols represent individual mice. Error bars 
represent means ± SEM. 
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Fig S3.5 The number of CD8+ TRM is reduced in B cell-deficient mice.  
µmT mice were infected by s.s. or i.n. with Δ12Δ203 and treated with α-CD4 or isotype control 
antibodies, as in Figure 2B. (A) Absolute number of B819-26-tetramer+ cells in the skin and spleen 
of µmT mice previously infected for 30 days is shown. n = 4-5 mice per group. Data are pooled 
from two independent experiments. Error bars represent means ± SEM. (B) Representative flow 
plot of CD103 expression on CD8+ T cells in the skin of µmT previously infected for 30 days is 
shown next to the percentage of CD103+ cells. n = 5 mice per group. Data are pooled from two 
independent experiments. Error bars represent means ± SEM. 
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Chapter 4: 
Discussion and Future Directions 
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Discussion 
Over 200 years ago, Edward Jenner had a theory that prior exposure to CPXV could 
provide protection against smallpox. He tested his theory in 1796 by inoculating a child with 
CPXV taken from a cowpox pustule and showed that the child was indeed protected against 
smallpox. He also made an interesting observation that CPXV infection did not always protect 
against secondary infection with CPXV159. It is thus tempting to speculate that my findings on 
CPXV-mediated MHCI inhibition may explain this peculiar conundrum. The findings presented 
here should also be considered in regards to rationale vaccine design because many viruses 
possess the capacity to obstruct MHCI antigen presentation.    
Major infectious diseases caused by viruses that target the MHCI pathway include 
hepatitis C, symptomatic congenital CMV disease, and acquired immune deficiency syndrome 
(AIDS) 160,161. These viruses have propensities to evolve immune-escape mutations and 
mechanisms that can render antibody-based vaccines poorly effective162–164. Therefore, strategies 
aimed at eliciting strong CD8+ T cell responses and memory CD8+ T cell formation may be 
important for effective vaccine-induced immunity against such viruses. However, if these viruses 
effectively evade CD8+ T cell responses in vivo by interfering with MHCI antigen presentation, 
it will be worthwhile to develop strategies for targeting viral MHCI inhibitors or for augmenting 
MHCI antigen presentation. These strategy may be particularly useful in providing cures against 
persistent and latent viral infections (e.g. CMV and HIV infection), in which memory CD8+ T 
cells can potentially eliminate reactivated latent reservoirs but fail to do so because of viral 
MHCI inhibition119,165–167. 
The ability of viruses to inhibit MHCI presentation can however be exploited for vaccine 
vector development. For instance, viral MHCI inhibition by RhCMV allows the virus to 
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superinfect hosts that have established immunological memory to RhCMV72, making CMV 
viruses appealing as vaccine vectors168. Using a vaccine vector capable of superinfecting hosts 
could circumvent the issue of rapid vaccine vector neutralization by pre-existing memory, which 
can diminish immune responses against targeted vaccine antigens. Successful superinfections 
could also permit repeated vaccinations against different target antigens while using the same 
vaccine vector backbone. Such a feat may be difficult to achieve with vaccine vectors that cannot 
reinfect hosts harboring immunological memory against the respective vector, including some 
poxvirus-based vaccines. Nevertheless, it would be interesting to explore CPXV as a vaccine 
vector since my studies suggest that viral MHCI inhibition may permit CPXV to reinfect CPXV-
immunized hosts, although this has not been thoroughly tested. 
 
Future directions 
Memory CD8+ T cells, including TRM, may provide cross-protection against distinct viral 
strains 169–171. For instance, vaccine-generated lung TRM mediate heterosubtypic protection 
against respiratory infection with influenza virus 127. TRM have also been shown to provide 
protection in the skin and genital tract using a number of different viral infection models123,124,128, 
demonstrating that TRM can be excellent antiviral vaccine targets. An improved understanding of 
the processes that govern TRM development and activation may thus aid in the design of 
efficacious TRM-based vaccines. Others and myself have shown an important role for local 
cognate antigen in TRM development and activation133,134,136,172, yet the mode of local cognate 
antigen presentation (i.e. direct- or cross-presentation) used to prime or activate TRM remain to be 
elucidated. Determining the relative contribution of direct/cross-presentation and how these 
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modes of antigen presentation affects these processes is challenging, but can likely be addressed 
using the CPXV murine infection model.  
There are several advantages in using the CPXV infection model. One is that the priming 
of naïve CPXV-specific CD8+ T cell precursors during CPXV infection is dependent on BATF3+ 
DCs, the main cross-presenting DC subsets. Local BATF3+ DCs also remain uninfected at the 
site of infection, suggesting that BATF3+ DCs are actually cross-presenting antigen. Another 
important factor is that the contribution of direct presentation by CPXV-infected cells at the site 
of infection is likely minimized due to the effects of CPXV012 and CPXV203. These points 
strongly imply that cross-presenting BATF3+ DCs provide local antigenic stimulation to CTLs, 
thereby promoting TRM formation, but experiments to directly test this hypothesis need to be 
performed. Interestingly, the findings and points discussed here also raise the possibility that 
local cross-presentation may be involved in TRM activation. However, additional experiments are 
also required to determine the role of local cross-presentation during secondary CPXV infection. 
The CPXV infection model therefore provides an exceptional opportunity to investigate the 
mechanisms of local antigen-driven CD8+ TRM differentiation and activation; further studies with 
CPXV may ultimately facilitate the development of improved tissue-specific vaccine design. 
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